Oncology and Hematology: Recent Episodes
ReachMD
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Miguel-Angel Perales, MD
Guest: Anna Sureda, MD, PhD
Unfortunately, the treatment paradigm for acute graft-versus-host disease (aGVHD) has not changed for a couple of decades as steroids remain the first-line treatment.1 However, steroids are not a targeted therapy, and they have many side effects that are not well tolerated by patients, including life-threatening infections.1-3 Given these risks, it is important to know how to manage infections related to immunosuppression and optimize the care of patients with aGVHD. Joining Dr Charles Turck to discuss the current landscape of aGVHD management are Dr Miguel-Angel Perales and Dr Anna Sureda. Dr Miguel-Angel Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, and Dr Sureda is the Head of Clinical Hematology at the University of Barcelona in Spain.
References:
- Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease. Transplant Cell Ther. 2022;28(10):707.e1-707.e7. doi:10.1016/j.jtct.2022.04.014
- Sullivan PW, Ghushchyan VH, Globe G, Sucher B. Health-related quality of life associated with systemic steroids. Qual Life Res. 2017;26(4):1037-1058.
- García-Cadenas I, Rivera I, Martino R, et al. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow …
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Vivek Kaul, MD
The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Matthew Matasar, MD
When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient’s risk and personalize care plans regarding treatment selection and location, prophylactic regimen, and early intervention strategies. Tune in to hear Dr. Charles Turck and Dr. Matthew Matasar discuss the importance of these models in identifying individual factors, which can maximize the benefits of CAR T-cell therapy and reduce toxicities. Dr. Matasar is the Chief of the Division of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sairah Ahmed, MD
Guest: Caron A. Jacobson, MD
The side effects associated with CAR T-cell therapy are very different than those seen with other cancer therapies and include cytokine-release syndrome (CRS) and neurotoxicity. It’s important to know how to recognize the signs of these adverse events and treat patients with relapsed or refractory large B-cell lymphoma early to avoid drastic quality-of-life impacts. To help improve patient safety and decrease hospital utilization, Dr. Charles Turck speaks with Drs. Caron Jacobson and Sairah Ahmed about the proper identification and management of these side effects in patients receiving CAR T-cell therapy. Dr. Jacobson is the Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute in Boston, and Dr. Ahmed is an Associate Professor in the Department of Lymphoma and Myeloma Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.
Guest: Tara Graff, DO, MS
Host: Charles Turck, PharmD, BCPS, BCCCP
While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it’s associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strategies like aggressive hydration, prophylactic use of corticosteroids, early intervention with tocilizumab, and multidisciplinary care. Joining Dr. Charles Turck to share her insights into how we can lower the risks of CAR T-cell therapy is Dr. Tara Graff, a medical oncologist who leads a community-based clinical trial program at Mission Cancer and Blood in Des Moines, Iowa.
Host: Jacob Sands, MD
Guest: Julia Rotow, MD
In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laura Alder, MD
The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to identify biomarkers that can predict a patient’s response to therapy. That’s why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial’s findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Thomas Egenod, MD
In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.
Host: Jacob Sands, MD
Guest: Alex Spira, MD, PhD, FACP
Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial is examining the efficacy and safety of combining valemetostat and datopotamab deruxtecan (Dato-DXd). Here with Dr. Jacob Sands to talk about the study’s design and next steps is Dr. Alex Spira, Director of the Thoracic and Phase I Program at Virginia Cancer Specialists Research Institute and a Clinical Assistant Professor at Johns Hopkins.
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.
Host: Jacob Sands, MD
Guest: Aaron Lisberg, MD
Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That’s why there’s interest in identifying new therapies like datopotamab deruxtecan (Dato-DXd), which was found to improve overall survival based on an interim analysis. But what are the latest findings? Here to share the final overall survival data on Dato-DXd from the TROPION-Lung01 trial are Drs. Jacob Sands and Aaron Lisberg, who worked together on this research that was presented at the 2024 World Conference on Lung Cancer.
Host: Harry Yoon, MD
Guest: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Jaffer Ajani, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Harry Yoon, MD
This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inhibitor (ICI) to chemotherapy. Participants will learn about anti-PD-1 agents for ESCC that are either approved or are actively being investigated, along with their differentiating features; practice-changing data; and current guideline recommendations to inform first-line treatment selection decisions for patients with metastatic ESCC. Strategies to monitor and mitigate adverse effects associated with the use of combination ICI and chemotherapy regimens to optimize treatment adherence and patient outcomes will also be explored.
Please stay tuned for additional content to this program available for credit. The maximum amount of credit available for the entire activity 0.75.
Host: Brian Slomovitz, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
In recent years, the treatment landscape for recurrent or metastatic cervical cancer has undergone significant shifts with FDA approvals of first-line pembrolizumab plus platinum-doublet with or without bevacizumab and second-line tisotumab vedotin. The introduction of frontline immune checkpoint blockade also added to the challenges faced by clinicians as they choose optimal regimens for their patients. In this online CME activity, Dr. Coleman and Dr. Slomovitz offer strategies for treatment selection and sequencing with immune checkpoint inhibitors and antibody-drug conjugates for relapsed cervical cancer. Tune in to hear their expert perspectives on biomarker testing, clinical trial evidence, and multidisciplinary management of adverse events associated with these therapies to make sure your patients are getting the most out of these advances.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Luis Paz-Ares, MD, PhD
Host: Helena Yu, MD
Host: Matthew Gubens, MD, MS
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN), focuses on translating oncology guidelines into practical strategies for treating non-small cell lung cancer (NSCLC). Participants will learn how to integrate clinical trial data into guideline-concordant testing and treatment plans for patients with resectable and metastatic NSCLC. The program highlights the importance of evidence-based approaches in the perioperative setting and the use of immunotherapy and targeted therapies for advanced disease. Attendees will also explore emerging data that could influence future treatment guidelines and develop region-specific therapeutic strategies aligned with NCCN recommendations.
As of November 12, 2024, a new Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been submitted to the FDA for accelerated approval in the US for patients with previously treated advanced EGFR-mutated NSCLC. The previously submitted BLA for patients with advanced nonsquamous NSCLC has been voluntarily withdrawn.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Steven Maron, MD, MSc
Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.
References:
- The Cancer Genome Atlas Network. Nature. 2014;513:202-209.
- Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125.
- Yang B, et al. J Exp Clin Cancer Res. 2019;38:283.
- American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024.
- Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082.
©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24
Host: Joyce O'Shaughnessy, MD
Hormone receptor-positive, HER2-negative cancer is the most common subtype of breast cancer. Initial treatment consists of surgery with or without radiotherapy or chemoradiotherapy, followed by adjuvant endocrine therapy for 5 to 10 years. Although endocrine therapy improves outcomes in these patients, recurrence is high (40% to 60% of patients). In disease with no BRCA mutation, treatment intensification by adding a CDK4/6 inhibitor to endocrine therapy has been shown to improve survival outcomes in high-risk disease. This activity explores the role of CDK4/6 inhibitors in HR-positive, HER2-negative early breast cancer in a patient case vignette, with an emphasis on shared decision-making.
Host: David H. Ilson, MD, PhD
Guest: Sunnie Kim, MD
This educational activity delves into biomarker-driven strategies for first-line therapy in metastatic gastric and gastroesophageal junction (GEJ) cancers. Participants will explore the latest clinical trial data and emerging biomarkers that guide treatment decisions. Our experts emphasize selecting optimal therapies tailored to patient-specific factors and offer strategies for managing treatment-related adverse effects. Tune in to enhance treatment efficacy and patient outcomes for your patients with metastatic gastric/GEJ cancers.
Host: Matt Birnholz, MD
The SIMPLIFY-2 trial compared the efficacy of momelotinib to best available therapy, which was primarily continued ruxolitinib, in patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor. According to the findings, momelotinib potentially offers better outcomes and a more comprehensive management strategy by addressing the underlying molecular mechanism of anemia. Learn more about the trial design and results with Dr. Matt Birnholz.
Guest: Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
Guest: Jyoti Patel, MD
The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease.
Host: Sara M. Tolaney, MD, MPH
This Chairperson’s Perspective will provide an in-depth look at ADC-directed therapies for HR+/HER2-expressing metastatic breast cancer. Participants will explore current treatment options, emerging data, and best practices for selecting and sequencing therapies. The session will also cover strategies for managing adverse events associated with these treatments to optimize patient outcomes. Designed for healthcare professionals, this program aims to enhance clinical decision-making in the evolving landscape of metastatic breast cancer care.
Host: Jennifer Caudle, DO
Guest: A. Mark Fendrick, MD
Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn the details of this study and how we can incorporate the findings into practice, join Dr. Jennifer Caudle as she speaks with Dr. Mark Fendrick, Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan.
Host: Amir T. Fathi, MD
Guest: Courtney DiNardo, MD
Guest: Brian A. Jonas, MD, PhD
While the expanding arsenal of therapies available for patients with AML allows practitioners to further hone treatment and individualize care, the complexity of treatment decision-making requires careful consideration of potential risks and benefits of each treatment option. This real-world, case-based program will provide a format for community hematology-oncologists to hear current updates on the latest targeted therapies in AML and engage in pointed, practical discussions on how to best integrate these data into current and local AML treatment paradigms.
Host: Matthew S. Davids, MD, MMSc
This program addresses the educational needs for relapsed or refractory (R/R) B-cell leukemias and lymphomas, particularly chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and reveals crucial practice gaps. Key challenges include managing poor treatment responses and patient health deterioration, necessitating therapies that extend survival and improve quality of life. Noncovalent Bruton’s tyrosine kinase inhibitors (ncBTKi) show promise in these cases, but clinicians need updated knowledge on their use, including response rates and management of associated toxicities. Additionally, the evolving landscape of B-cell lymphoma therapies complicates treatment choices, requiring expert guidance on individualized therapy selection and sequencing.
Host: Caroline Piatek, MD
Guest: Irina Murakhovskaya, MD
Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes when they reach the clinic. Join Drs. Caroline Piatek and Irina Murakhovskaya as they discuss in detail current and emerging non-antibody and monoclonal antibody therapies for wAIHA and how each has the potential to dramatically improve the treatment landscape for wAIHA.
Host: Helena Yu, MD
The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity.
Host: Shubham Pant, MD, MBBS
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Shubham Pant, MD, MBBS
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Shubham Pant, MD, MBBS
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Shubham Pant, MD, MBBS
Host: Ritu Salani, MD, MBA
This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.
Host: Jennifer Caudle, DO
Guest: Samuel R. Wilson, MD
Sickle cell disease is among the most common inherited conditions globally, affecting more than seven million individuals worldwide.1-3 Given its prevalence, it is important to understand all of the complexities surrounding this disease. Joining Dr. Jennifer Caudle to discuss the pathophysiology, clinical presentation, burden, and unmet needs of sickle cell disease is Dr. Samuel R. Wilson, Assistant Professor of Medicine in the Division of Hematology at the University of North Carolina School of Medicine.
References:
- Sedrak A, Kondamudi NP. Sickle cell disease. StatPearls Publishing; 2023. Updated August 12, 2023. Accessed April 16, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482384/.
- Thomson AM, McHugh TA, Oron AP, et al. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(8):e585-e599. doi:10.1016/S2352-3026(23)00118-7.
- CDC. Data & statistics on sickle cell disease. Centers for Disease Control and Prevention. Published May 2, 2022. Accessed April 16, 2024. https://www.cdc.gov/ncbddd/sicklecell/data.html/.
Agios Pharmaceuticals, Inc. © 2024
All right reserved.
SCD-US-0095 / June 2024
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Talha Munir, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Thomas Kipps, MD, PhD
Host: William Wierda, MD, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Talha Munir, PhD
Determining the optimal treatment regimen for patients with chronic lymphocytic leukemia (CLL) has been a clinical challenge, especially since most patients are older than 70 years, present with significant coexisting comorbidities, and exhibit one or more common chromosomal alterations. However, outcomes in CLL are improving with the availability of non-chemotherapy options with fewer toxicities. Fixed-duration therapy has emerged as an even more attractive approach for the frontline treatment of CLL and is associated with mild toxicities, improved treatment adherence and monitoring, and reduced financial burden. Embark on a journey through this educational series to achieve a better understanding of the rationale and supporting clinical data for fixed-duration therapy, monitoring strategies, the role of MRD-guided treatment selection, and approaches to overcome relapsed/refractory CLL.
Host: Saad Z. Usmani, MD, MBA, FACP
Guest: Joshua Richter, MD
Guest: Ashley Steinberger, APP
Release date: 8/15/2024
Expiration date: 8/15/2025
Estimated time to complete: 1.0 hour
This activity is not accredited for CME/CE credit.
This episode of Myeloma Matters reviews the latest data on bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM) discussed at the 2024 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including information about the use of fixed-duration dosing to mitigate adverse events (AEs).
The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in managing RRMM. Expert faculty will place abstract findings into clinical context and discuss strategies for preventing and managing AEs associated with bispecific antibody therapy in RRMM treatment, which include cytokine release syndrome (CRS), neurotoxicity, and infection.
Host: Justin Gainor, MD
Guest: Jacob Sands, MD
The treatment landscape of non-small cell lung cancer (NSCLC) has dramatically changed over the past 20 years. In recent years, the discovery of targetable molecular alterations and the development of targeted therapies have dramatically changed the treatment outlook for NSCLC. Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene. Its activation affects downstream signaling pathways implicated in cell proliferation, survival, differentiation, and migration. The inclusion of HER2-directed antibody-drug conjugate (ADC) therapy in lung cancer is relatively new; these agents have been shown to greatly improve outcomes in patients with HER2-expressing NSCLC. In this case-based activity, expert faculty illustrate best practices for the use of HER2-directed ADCs in NSCLC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jessie Hsieh, MD
Guest: David Isaacson, MD
About 70 percent of all cancer-related deaths are associated with cancers that don't have recommended USPSTF screening modalities.1 But the good news is that adding multicancer early detection (MCED) testing to usual care screenings could help address this gap and potentially improve outcomes by screening for more cancer types. Joining Dr. Charles Turck to share their experiences with MCED testing and a real-world patient case are Drs. Jesse Hsieh and David Isaacson. Dr. Hsieh is the Chairman of the Board of Beacon Health System in Indiana, and Dr. Isaacson is an Assistant Professor of Otolaryngology at the Indiana University School of Medicine.
Reference:
- Estimated deaths per year in 2022 from American Cancer Society Cancer Facts and Figures 2022. Available at:
http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/cancer-facts-and-figures-2022.pdf. Data on file GA-2021-0065
Host: Josep Tabernero, MD, PhD
Guest: Sara Lonardi, MD
Guest: Zev A. Wainberg, MD
Join us for a CME online broadcast replay of a live satellite symposium from ESMO GI 2024, where experts discuss strategies to overcome barriers to implementing a collaborative, biomarker-based approach in precision oncology for HER2+ GI cancers. Learn how to individualize therapeutic planning and sequencing for patients with HER2+ gastric/GEJ cancers and improve response and durability in mCRC with HER2-directed therapies. The symposium also covers the role of genomic profiling in guiding treatment decisions for HER2+ BTC and emphasizes the importance of interprofessional collaboration in managing adverse events associated with HER2-directed therapies in patients with GI cancer.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christopher Chambers, MD
Guest: Adam H. Buchanan, MS, MPH
Since multi-cancer early detection (MCED) testing is a new technology, there’s been some discussion in the field about the impact it may have on patients, especially in terms of potential psychological harm like anxiety related to positive test results and false positive test results. Joining Dr. Charles Turck to discuss findings from a recent qualitative survey and the DETECT-A study focusing on how MCED testing may impact patient anxiety are Dr. Christopher Chambers and Mr. Adam Buchanan. Dr. Chambers is a Professor and Director of Clinical Trials at Thomas Jefferson University in Philadelphia, and Mr. Buchanan is an Associate Professor and Chair of the Department of Genomic Health at Geisinger in Danville, Pennsylvania.
Host: Jody Takemoto, PhD
Guest: David Braun
Identifying biomarkers for renal cell carcinoma (RCC) is critical since they can help direct our therapeutic approach, which is why several techniques that may be able to uncover new biomarkers are currently being investigated. Joining Dr. Jody Takemoto to review those techniques and their potential impacts on RCC care is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Host: Jody Takemoto, PhD
Guest: David Braun, MD, PhD
A recent study investigated whether renal cell carcinoma (RCC) molecular subtypes have any impact on treatment outcomes. Here to share the surprising findings and their implications is Dr. David Braun, Assistant Professor of Medicine and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center.
Host: Matthew S. Davids, MD, MMSc
Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL.
In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can …
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
Since the guidelines for diagnosing and treating hepatocellular carcinoma are often lengthy and complicated, it can be difficult for clinicians to stay up to date on the current recommendations and implement them in clinical practice. That’s why a team with the HCC Steering Committee of the Chronic Liver Disease Foundation developed a web-based, interactive tool that incorporates current guideline recommendations to help clinicians diagnose and treat patients with hepatocellular carcinoma. To learn more about this tool, Dr. Jody Takemoto speaks with Dr. Robert Wong. Not only is he a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine, but he also helped develop the tool.
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Joshua E. Reuss, MD
Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC.
In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are …
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: John Mascarenhas, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Gabriela Hobbs, MD
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Host: Jason Hafron, MD
Guest: Carissa Chu. MD
Despite treatment advances in genitourinary cancers, most patients will develop relapsed disease. Thus, new treatment approaches are needed, as well as improved methods to identify patients who will derive the optimal benefit from established and emerging therapies. Real-world data provide crucial insight into practice patterns and response rates, ultimately guiding individualization of treatment selection. In this activity, expert faculty assess key findings from prostate and bladder cancer trials and explore the relevance of these data to clinical practice.
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Patrick Forde, M.B.B.Ch.
Guest: Jarushka Naidoo, MBBCh, MHS
Struggling to navigate the latest immunotherapy options for advanced NSCLC? This online CME program delves into optimizing dual immune checkpoint inhibitor therapy for patients with driver-negative advanced NSCLC. Learn how to leverage recent clinical trial data and patient characteristics to individualize treatment for the best possible outcomes, including for those with challenging brain metastases.
Host: Ghassan K. Abou-Alfa, MD
Guest: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
Host: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
Guest: Aiwu Ruth He, MD, PhD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Host: Ghassan K. Abou-Alfa, MD
This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable hepatocellular carcinoma (HCC). Participants will critically assess survival outcomes and other key efficacy metrics from recent studies. The program emphasizes the application of efficacy and safety data to tailor treatment regimens based on individual patient profiles and preferences. Additionally, it addresses the recognition and management of treatment-related adverse events associated with these regimens. The course also incorporates strategies for effective communication and shared decision-making within the multidisciplinary care team, ensuring optimal patient-centered care.
Guest: Elizabeth Montgomery, MD
Guest: John L. Marshall, MD
This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing, benefits of tissue versus liquid biopsy, when to test and why, and the use of biomarkers in prediction and prognosis. Finally, individualizing the treatment of mCRC based on molecular (eg, RAS, BRAF, MSI-high, HER2), patient (eg, comorbidities, age), and tumor (location, resectability) characteristics, as well as patient preferences (quality of life, treatment toxicities) will be discussed.
Host: Brian P. McDonough, MD, FAAFP
Guest: Betsy O'Donnell, MD
Guest: Tomasz Beer, MD, FACP
Should a patient get a positive multi-cancer early detection (MCED) test result, there are two diagnostic resolution pathways proposed for localizing and confirming that result. Joining Dr. Brian McDonough to break down those two pathways and how we can optimize our approach to diagnostic resolution are Drs. Betsy O’Donnell and Tom Beer. Dr. O’Donnell is the Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute, and Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Guest: Phillip H. Kuo, MD, PhD
One of the major changes that's occurred very recently in the field of neurodegenerative disease and Alzheimer's disease, specifically, are the recently approved antibody therapies that remove amyloid from the brain, which is one of the culprit proteins in Alzheimer's disease. To learn more about this presentation from SNMMI 2024, join Dr. Phillip Kuo, Professor of Medical Imaging, Medicine, and Biomedical Engineering at the University of Arizona.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
Hepatitis B is one of the leading causes of liver cancer globally, underscoring the importance of screening, diagnosing, and treating patients appropriately. However, there are several considerations to keep in mind when caring for patients with hepatocellular carcinoma with hepatitis B co-infection, which is why Dr. Jody Takemoto speaks with Dr. Robert Wong about those factors and essential management strategies. Dr. Wong is a Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine.
Host: Jody Takemoto, PhD
Guest: Robert Wong, MD
A recent study explored clinician-level gaps and barriers to hepatocellular carcinoma surveillance in patients with cirrhosis and found that there is a lot of work to be done to help improve knowledge about cirrhosis, the recommended cancer screening guidelines, and how to implement those recommendations. Joining Dr. Jody Takemoto to discuss these findings and how we can address the uncovered challenges is Dr. Robert Wong, Clinical Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Stanford University School of Medicine.
Host: Jennifer Caudle, DO
Guest: Patricia A. Mangan, RN, MSN, APRN-BC
The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting.
Guest: Geoffrey B. Johnson, M.D., Ph.D.
When looking at patients who suffer from prostate cancer who are receiving PSMA therapy, we can see on our images that the medication not only goes to their cancer, but it also goes to some other things in their body, including the salivary glands. To learn more about his recent study on salivary toxicity, join Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
Host: Jennifer Caudle, DO
Guest: Geoffrey B. Johnson, M.D., Ph.D.
Prostate-specific membrane antigen (PSMA) PET scans are a method by which clinicians can see if a patient who is suffering from prostate cancer has tumors that are expressing the PSMA target. In addition to that, the scan allows us to measure how much of the medication we get onto that cancer target and if it’s going to be effective. Take a deep dive with Dr. Jennifer Caudle as she speaks with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota, who also presented this research at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting.
Guest: Geoffrey B. Johnson, M.D., Ph.D.
Clinicians are hopeful that theranostics could help treat patients as soon as they go metastatic or even before surgery to try to affect their therapy and possibly get them to avoid having to take toxic or high side effect therapies. To hear more, tune in with Dr. Geoffrey Johnson, Nuclear Medicine Specialist and Radiologist at the Mayo Clinic in Rochester, Minnesota.
Guest: Chi Liu, PhD
The field of artificial intelligence in nuclear medicine is evolving quickly with new models and approaches. Tune in with Dr. Chi Liu, Professor of Radiology and Biomedical Engineering at Yale University, to hear more about his presentation from SNMMI 2024.
Guest: Brianna Cagle
The Discovery Team at Perspective has developed a compound, called PSV-359, which is a cyclic peptide radiopharmaceutical. It targets a protein, called fibroblast activation protein (FAP), which is a pan-cancer target and is expressed in a wide variety of cancers. To learn more about her presentation from SNMMI 2024, hear from Brianna Cagle, Research Scientist at Perspective Therapeutics in Iowa.
Guest: Lillian Siu, MD, FRCPC
Since cancer vaccines have been of interest to oncologists for decades, they’ve been trying to figure out how to prime or stimulate the immune system to attack cancer, and until the last few years, cancer vaccines have been challenging. To learn about this unique area of study, which she also presented at ASCO 2024, join Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and a Professor of Medicine at the University of Toronto.
Host: Jody Takemoto, PhD
Guest: Bryson Katona, MD, PhD
At the 2024 Digestive Disease Week Annual Meeting, Dr. Bryson Katona presented a session, titled “High-Risk Colon Cancer: The ABCs of Genetic Testing.” And now, Dr. Katona is here with Dr. Jody Takemoto to share key insights from his session on genetic testing for patients with high-risk colon cancer. Dr. Katona is the Director of the Gastrointestinal Cancer Genetics Program and Risk Evaluation Program and the Lynch Syndrome Program at Penn Medicine
Host: Brian P. McDonough, MD, FAAFP
Guest: Nima Nabavizadeh, MD
Guest: Tomasz Beer, MD, FACP
While multi-cancer early detection (MCED) testing has the potential to significantly impact the way we approach cancer screening, it’s important to be aware of the risks associated with it, like overdiagnosis. That’s why Drs. Nima Nabavizadeh and Tom Beer join Dr. Brian McDonough to discuss the advantages and drawbacks of MCED testing and how we can mitigate the risk of overdiagnosis. Dr. Nabavizadeh is an Associate Professor in the Department of Radiation Medicine in the School of Medicine at OHSU in Portland, Oregon, and Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Guest: Lillian Siu, MD, FRCPC
With a few studies in the works for cancer vaccines, the future is exciting for what this could mean for oncology patients. Dive in to learn about the various ways to package cancer vaccines so they can be delivered to patients effectively. And to learn more about the limitations, targets, and platforms of cancer vaccines, which was the topic of her presentation at the American Society of Clinical Oncology 2024 Conference, hear from Dr. Lillian Siu, Senior Medical Oncologist at the Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto.
Guest: Ashley L. Sumrall, MD
If we want to ensure that we and our patients have healthcare when we’re older and it continues to be available, it’s important to take a stand and be a part of advocacy work. There are multiple ways to get involved, and it’s not as intimidating as someone might think, so to share some of these strategies and the impact it could have on the future of healthcare, join Dr. Ashely Sumrall, Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
Guest: Ashley L. Sumrall, MD
Advocacy is rooted in patients telling their stories, and every patient can be an advocate to help and allow others to hear about their experience. This has also helped clinicians get the medicine they need for their patients. Dive in to hear how you can incorporate advocacy strategies into your practice with Dr. Ashley Sumrall, Neuro- and Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
Guest: Tyler J Bradshaw, PhD
In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more about these new technologies and imaging agents, join Dr. Tyler Bradshaw, Associate Professor in the Department of Radiology at the University of Wisconsin-Madison, who presented this topic at the SNMMI 2024 Annual Meeting.
Host: Joseph Kim, MD, MPH
This video brief will discuss quality improvement in myelofibrosis management. To highlight ways to improve care for patients with both primary and secondary myelofibrosis, we’ll examine the experiences of two cancer centers that engaged in quality improvement programs.
- Molecular Testing
- Symptom Assessment
- Prognostic Risk Assessment
- JAK Inhibitor Therapy
- Shared Decision-Making
- Interprofessional Team-Based Care Coordination
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
- Gormley M, et al. Br Dent J. 2022;233(9):780-786.
- Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024
Host: Matthew Lunning, DO, FACP
In the rapidly evolving landscape of treating patients with relapsed or refractory large/diffuse large B-cell lymphoma (R/R LBCL/DLBCL), recent advancements are providing newfound hope. Immunochemotherapy with R-CHOP has long been the standard first-line treatment, but a significant portion of patients experience relapses and refractory disease. Until recently, salvage chemotherapy followed by autologous stem cell transplant (ASCT) was the only curative option. However, the introduction of novel therapies including T-cell engaging therapies has sparked a paradigm shift in R/R LBCL/DLBCL management.
In this transforming landscape, bispecific antibodies (BsAbs) stand out as a remarkable addition. They offer readily available, "off-the-shelf" options that do not require a manufacturing process tailored to each patient, with the advantage of lower rates of severe side effects compared to CAR T-cell therapy, making them a promising choice, particularly for older patients and those with late-stage disease.
This web-based, on-demand activity highlights key clinical trial evidence for bispecific antibodies targeting CD20 and CD3, and how to contextualize the rationale for and clinical utility of integrating CD20 X CD3 bispecific antibodies into community-based clinical practice. Expert faculty offer insights and advice based on their own real-world clinical practice experiences regarding the management and treatment of R/R DLBCL/LBCL and appropriate …
Host: Jennifer Caudle, DO
Guest: Joyce O'Shaughnessy, MD
The results from the phase III EMERALD trial led to the approval of ORSERDU® (elacestrant) as the first oral selective estrogen receptor degrader for ER-positive/HER2-negative metastatic breast cancer patients with ESR1 mutations after disease progression following at least one line of endocrine therapy.1 But given the results from prior analyses, clinicians wanted to better understand the data for elacestrant in subgroups of patients with key clinical or biomarker characteristics, and so a post hoc analysis of elacestrant in these subgroups who typically have a poorer prognosis was conducted. Explore the EMERALD trial and the key outcomes from this subgroup analysis with Dr. Jennifer Caudle and medical oncologist Dr. Joyce O'Shaughnessy.
Host: Brian P. McDonough, MD, FAAFP
Guest: Frank Diehl, PhD
A poster presented at the 2024 American Association for Cancer Research Annual Meeting showcased findings from the ASCEND 2 study, which examined the performance of a multi-cancer early detection (MCED) test design that included methylation and protein biomarkers. The study found that this test design achieved overall sensitivity of 50.9 percent for all cancers at a high specificity of 98.5 percent. Dive further into these results and what they might mean for early cancer detection with Dr. Brian McDonough and Dr. Frank Diehl, Senior Vice President of Multi Cancer Early Detection at Exact Sciences Corporation.
Host: Joshua E. Reuss, MD
Guest: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
Guest: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
Guest: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Jhanelle E. Gray, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Joshua E. Reuss, MD
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Host: Mazyar Shadman, MD, MPH
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP
Guest: Barbara Burtness, MD
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Allison Betof Warner, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Hussein Tawbi, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Allison Betof Warner, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Allison Betof Warner, MD, PhD
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Host: Cem Akin, MD, PhD
Guest: Daniel J. DeAngelo, MD, PhD
New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report that systemic mastocytosis and ISM are often undiagnosed for years. Improve your diagnosis and treatment of ISM by tapping into the expertise of a multidisciplinary team, including allergists, gastroenterologists, and hematologists, and increase your awareness of diagnostic criteria, the varied presentations of ISM, and new treatment options that move beyond traditional anti-mediator therapy.
Host: Cem Akin, MD, PhD
Guest: Daniel J. DeAngelo, MD, PhD
Guest: Matthew J. Hamilton, MD
Patients with indolent systemic mastocytosis frequently report a symptom burden disproportionate to measurable disease burden. Anti-mediator intervention is not always successful in improving the quality of life of these patients. But the treatment landscape is changing. Join Drs. Cem Akin, Daniel DeAngelo, and Matthew Hamilton offer key clinical insights into this changing standard of care for ISM and discuss why allergists, hematologists, and gastroenterologists are at the vanguard of this change.
Host: Jeffrey V. Matous, MD
Guest: Donna Catamero, NP
Guest: Ajai Chari, MD
GPRC5D-directed therapy is associated with impressive overall response rates and substantially positive clinical outcomes in heavily pretreated relapsed/refractory multiple myeloma. Identification and appropriate management of treatment-emergent adverse events is important to ensure that patients can stay on therapy safely to achieve optimal outcomes. In this educational podcast, myeloma experts weigh in on best-practice management strategies for these toxicities.
Host: Meghan Mooradian, MD
This Patient Clinician Connection CME activity, led by Dr. Meghan Mooradian, focuses on the use of adjuvant immunotherapy in early-stage melanoma. The activity aims to educate clinicians on the role of immunotherapy in reducing the risk of disease recurrence post-surgery, particularly in patients with resected stage IIB to III melanoma. Through patient clinical vignettes and audience education vignettes, participants will gain insights into patient-centered approaches, shared decision-making, and the management of immune-related adverse events associated with adjuvant immunotherapy, ultimately enhancing their ability to optimize treatment outcomes and patient care in this setting.
Host: Caitlin Costello, MD
Guest: Sagar Lonial, MD, FACP
Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and Lonial as they explore a case study that demonstrates how to select patients, prepare them for treatment, and effectively manage treatment-related side effects.
Host: David J. Kuter, MD, DPhil
Guest: Spero R. Cataland, MD
Guest: Catherine Broome, MD
Guest: Cindy Neunert, MD, MSCS
Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge and experience necessary to identify, diagnose, and treat them in accordance with best practices. As a result, there are significant gaps in care, including delays in diagnosis and suboptimal treatment. To ensure that more patients with these rare disorders are offered quality, evidence-based care, it’s essential that healthcare providers possess up-to-date information about best practices and new developments in this area of medicine. In this activity, composed of 3 podcasts, an expert moderator will interview 3 expert faculty members about evidence-based guidelines for the diagnosis and treatment of acquired thrombotic thrombocytopenic purpura, developments in the diagnosis and treatment of cold agglutinin disease, and the challenges of achieving enduring remission in patients with immune thrombocytopenia.
Host: Caitlin Costello, MD
Guest: Sagar Lonial, MD, FACP
Dive into the cutting-edge realm of bispecific antibodies for relapsed/refractory multiple myeloma with our experts, Dr. Caitlin Costello and Dr. Sagar Lonial. They explore the efficacy, safety, and practical integration of bispecific antibodies into clinical practice. Tune in to gain invaluable insights on optimizing patient care and navigating treatment-related adverse events to elevate your oncology practice.
Host: Jyoti Patel, MD
Guest: Pasi Antero Jänne, MD, PhD
Dive into the forefront of precision oncology with Drs. Pasi Janne and Jyoti Patel, where they unravel the potential of HER3-directed antibody-drug conjugates (ADCs) in revolutionizing treatment for NSCLC. Discover the transformative potential of HER3-directed ADCs in overcoming resistance to EGFR-targeted TKI therapies. This program offers a unique blend of trial results and practical strategies through the lens of a clinical case. Join us to lead the change in cancer care.
Host: Helena Yu, MD
Dr. Helena Yu of Memorial Sloan Kettering Cancer Center presents an insightful overview of HER2 targeted therapy in non-small cell lung cancer (NSCLC), emphasizing the critical role of broad molecular profiling in ensuring effective treatment, particularly for the 2-4% of NSCLC patients with HER2 mutations. Dr. Yu highlights the effectiveness of newer antibody–drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd) for NSCLC with HER2 mutations, while also detailing identification and management of potential side effects. Through a patient engagement vignette, she underscores the importance of aligning treatment choices with patient and clinician goals, highlighting shared decision-making in managing HER2-mutant NSCLC.
Host: Benjamin Levy, MD
Guest: Alexander Spira, MD, PhD, FACP
Drs. Benjamin Levy and Alex Spira discuss the emerging role of TROP2 as a therapeutic target in non-small cell lung cancer (NSCLC) on ReachMD. They delve into the mechanisms and clinical implications of TROP2-targeted antibody-drug conjugates (ADCs), highlighting ongoing clinical trials evaluating their safety and efficacy. The conversation covers the potential of these therapies to change treatment paradigms, especially in the context of TROP2 overexpression associated with poor prognosis in lung cancers. They also address the nuances of managing side effects and the importance of understanding TROP2's role in cancer regulation, underscoring the significance of keeping up-to-date with the latest clinical trial data in this rapidly evolving field.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Alexander Drilon, MD
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Charu Aggarwal, MD, MPH
This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Sagar Lonial, MD, FACP
Guest: Caitlin Costello, MD
"Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma” is a multiepisodic CME series exploring the role of bispecific antibodies for the treatment of heavily pretreated relapsed myeloma. Join our experts as they discuss the rationale for using these agents in the treatment of myeloma, strategies to monitor and manage treatment-related adverse events, and the pivotal data leading to the approval of these agents for relapsed myeloma.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Samuel J. Klempner, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Yelena Janjigian, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Host: Samuel J. Klempner, MD
The therapeutic landscape for gastric and gastroesophageal junction (G/GEJ) cancer is rapidly evolving, with biomarkers directing treatment selection. Recent evidence suggests that the combination of HER2-targeted therapies and immune checkpoint inhibitors has synergistic effects, highlighting the importance of the most recent clinical data regarding first-line treatments for advanced or metastatic G/GEJ cancers and the differentiation between HER2-positive and -negative tumors. In addition to HER2, Claudin 18 splice variant 2 (CLDN18.2) has emerged as a new biomarker for targeted treatment. Multiple factors should be considered in first-line treatment selection, including biomarker positivity, performance status, and potential toxicity. In this program, topics presented by expert faculty will illustrate the biomarker-related clinicopathologic features of G/GEJ cancers as well as how to incorporate the latest evidence to individualize first-line treatment for patients with G/GEJ cancers.
Please stay tuned for additional content to this program available for credit. MedEd On The Go will track the episodes you watch and provide you with the option to claim credit once you have reached the level of participation needed in order to claim. The maximum amount of credits available for the entire activity is 1.25.
Guest: Caron A. Jacobson, MD
CD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR T-cell therapies have historically been given in the inpatient setting, interest in outpatient delivery is growing, and this option may become more feasible if logistical issues and lack of multidisciplinary collaboration between the community provider and the CAR-T cell therapy center can be overcome.
AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies.
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Host: Kathleen Moore, MD, MS
Guest: Susana Banerjee, MBBS, MA, FRCP, PhD
Guest: Shubham Pant, MD, MBBS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Brad McGregor, MD
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Shubham Pant, MD, MBBS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Host: Kathleen Moore, MD, MS
Guest: Brad McGregor, MD
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Shubham Pant, MD, MBBS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Susana Banerjee, MBBS, MA, FRCP, PhD
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Colleen Kelly
Guest: Andrea Banty, DNP, FNP
Explore this series of three modules on C difficile infection and the impact of gut dysbiosis on the development of recurrent disease with Dr. Colleen Kelly, Associate Professor of Medicine in the Division of Gastroenterology at Warren Alpert Medical School of Brown University in Providence, Rhode Island, and Andrea Banty, Nurse Practitioner of Gastroenterology at Cedars-Sinai IBD Center in Los Angeles.
Guest: James M. Cleary, MD, PhD
Guest: Kathleen Madden, FNP, MSN, AOCNP, APHN
This on-demand features an expert case discussion on the current landscape of gastric cancer, from patient selection to treatment management to maximize benefit. Join Dr. James M. Cleary, Associate Professor of Medicine at Harvard Medical School, and Kathleen Madden, Family Nuse Practitioner at the Melanoma Program at NYU Langone Perlmutter Cancer Center in New York, NY, to learn more.
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Kathleen Moore, MD, MS
HER2-targeted treatments have been extensively researched and approved in breast, gastric, and non-small cell lung cancers. Are these same therapies effective at treating other HER2-positive tumors? Join our faculty as they examine the potential role for HER2-directed antibody-drug conjugates in treating advanced solid tumors and discuss the latest data around the efficacy and safety of these agents.
On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
Guest: Terry Faleye, MPAS, PA-C
Guest: Jonathan I. Silverberg, MD, PhD, MPH
Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel and more effective treatment options have been approved, including those targeting interleukin (IL)-13. Tune in to watch this webcast on incorporating these agents to optimize care for patients with moderate to severe AD with Terry Faleye, Dermatology Physician Assistant at DermSurgery Associates in Houston, Texas, and Dr. Jonathan Silverberg, Professor, Director of Clinical Research, and Director of Patch Testing at George Washington University School of Medicine and Health Sciences in Washington, DC.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Mary Weinstein Dunn
Learn about evolving standards in the care of patients with advanced renal cell carcinoma in this on-demand webcast capturing a live presentation by Mary Weinstein Dunn, MSN, NP-C, OCN, RN.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Frank dela Rama, RN, MS, AOCNS, AGN-BC
Learn about the APP’s evolving role in caring for patients receiving PARP inhibitors for prostate cancer in this on-demand webcast capturing a live presentation by Clinical Nurse Specialist Frank dela Rama, RN, MS, AOCNS, AGN-BC.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Rasheda Persinger MSN, AGNP-C, AOCNP
Learn from a leading expert in the field about the most recent recommendations for biomarker/molecular testing and personalized treatment plans for patients with non-small-cell lung cancer (NSCLC) based on testing results.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Robert Lentz, MD
Get up to date with this on-demand webcast from a live symposium focused on the latest approaches to treating patients with metastatic colorectal cancer, including immunotherapy and targeted therapy strategies.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Jeremy Force
Get up to date on how APPs can optimize care for patients with HER2-positive breast cancer in this on-demand webcast capturing a live presentation by Dr Jeremy Force.
Guest: Donna Ryan, MD
Guest: Daniel Zalinov, PA-C
Guest: Megan Adelman, PharmD, BCPS, BCGP, CDCES
Experts review best practices for the incorporation of motivational interviewing and shared decision-making strategies to improve the treatment of obesity. Tune in with Dr. Megan Adelman, Clinical Pharmacist of Family Medicine at Cleveland Clinic Akron General in Ohio, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Daniel Zalinov, Physician Assistant who specializes in Internal Medicine at Atrium Health in Charlotte, North Carolina.
Guest: Donna Ryan, MD
Guest: Caroline M. Apovian, MD, FTOS
Guest: Susan M. Tiso, DNP, APRN, FNP-BC, FAANP
Experts review guideline-recommended criteria for diagnosis and treatment of obesity and describe best practices for prioritization of obesity management. Tune in to learn more with Dr. Caroline Apovian, Co-Director at Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Donna Ryan, Professor Emerita at Pennington Biomedical Research Center in Baton Rouge, Louisiana, and Dr. Susan M. Tiso, Retired Family Nurse Practitioner from Family Medicine at the University of California, Irvine.
Guest: Caroline M. Apovian, MD, FTOS
Guest: Daniel Zalinov, PA-C
Guest: W. Scott Butsch, MD, MSc
Experts provide practical suggestions for incorporating obesity management into clinical practice and designing a comprehensive obesity care clinic. Dive in for more with Dr. Caroline Apovian, Co-Director of Center for Weight Management and Wellness at Brigham and Women’s Hospital in Boston, Dr. Scott Butsch, Director of Obesity Medicine at Bariatric and Metabolic Institute in Cleveland, Ohio, and Daniel Zalinov, Physician Assistant of Internal Medicine at Atrium Health in Charlotte, North Carolina.
Host: Ezra Cohen, MD, FRCPSC, FASCO
Guest: Sue S. Yom, MD, PhD
The emergence of early clinical endpoints compared to the current gold standard of overall survival may change the landscape of how clinical trials are designed as well as how patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) are managed. At the forefront of this change are unique small molecule agents that help to overcome the inhibitory influence of tumors on the apoptotic pathway. Join Drs. Ezra Cohen and Susan Yom as they focus on why utilizing early endpoints in clinical trials, and eventually the clinic, may provide therapeutic advantages compared to our current gold standard of overall survival.
Host: Jonathan D. Schoenfeld, MD, MPhil, MPH
Guest: Robert L. Ferris, MD, PhD
The treatment of LA SCCHN has remained largely unchanged for >2 decades and the standard of care, concurrent chemoradiotherapy (CRT) with high-dose cisplatin, is associated with substantial toxicity and limited efficacy. Inhibitors of apoptosis proteins (IAPs) may well change that dynamic. Join Drs. Jonathan Schoenfeld and Robert Ferris as they focus attention on this unmet need and critically evaluate how therapeutic modulation of the apoptotic pathway may improve patient outcomes.
Host: Heather Wakelee, MD, FASCO
Guest: Lyudmila Bazhenova, MD
We now have FDA approved targeted therapies to treat NSCLC with EGFR exon 20 insertion mutations. Drs. Wakelee and Bazhenova discuss the most current data on both approved therapies and drugs in development.
Host: Christopher M. Gallagher, MD
Host: Adam Brufsky, MD, PhD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Adam Brufsky, MD, PhD
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Adam Brufsky, MD, PhD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Adam Brufsky, MD, PhD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Adam Brufsky, MD, PhD
Host: Christopher M. Gallagher, MD
This program focuses on increasing clinician familiarity and comfort with real-world evidence (RWE) of CDK4/6 inhibitors in metastatic breast cancer (MBC) and clinicians’ confidence in their ability to discuss RWE with their patients.
Host: Pranshu Mohindra, MD
Guest: Melissa Teply, MD
Guest: Judith Paice, PhD, RN
Guest: Fionnuala Crowley, MD
This enduring program of the live-virtual symposium will focus on the challenges of managing cancer pain using the Evolve KOL Knockout™ case-based format. The key opinion leaders (KOLs) will be challenged by the host/moderator to diagnose and manage patient scenarios with varying levels of difficulty. Learners will vote on the winner of each case presentation round and the moderator will declare a match winner at the conclusion.
There will be learning, laughter, and only one KOL left standing!
Host: Joshua E. Reuss, MD
Host: Jessica S. Donington, MD, MSCR
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
Host: Joshua E. Reuss, MD
Host: Jessica S. Donington, MD, MSCR
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
Host: Joshua E. Reuss, MD
Host: Jessica S. Donington, MD, MSCR
The objective of this program is to enhance knowledge and awareness of the latest clinical trial data for immune checkpoint inhibitors (ICIs) that have been approved for use in the perioperative setting. Furthermore, the program aims to improve clinicians’ understanding of the ideal candidates for neoadjuvant/adjuvant ICI therapy, the sequencing of agents, and the challenges associated with comparing treatments across trials with varying criteria.
Through our focused microlearning approach, we will explore the ongoing debate surrounding the optimal timing of immunotherapy in relation to surgery. We will also delve into the role of predictive biomarkers in therapy selection and address the question of whether there is a universally “best” approach for choosing between neoadjuvant or adjuvant therapy, or if a personalized approach to treatment should be adopted for each patient.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Host: Ticiana Leal, MD
Host: Jacob Sands, MD
In the context of extensive-stage small-cell lung cancer (ES-SCLC), the optimal choice of second-line treatment following standard-of-care first-line platinum-based chemoimmunotherapy and maintenance immunotherapy is not clearly defined. Making therapeutic decisions requires careful consideration of various factors, including the choice of first-line treatment, the treatment-free interval (TFI) after first-line chemotherapy (whether the disease is platinum-sensitive or platinum-resistant), performance status, therapy-related toxicities, and contraindications. This program offers case studies presented by expert faculty to illustrate how the latest evidence and guidelines can be incorporated to personalize second-line treatment plans for patients with ES-SCLC.
Guest: Jacob Sands, MD
Host: Charu Aggarwal, MD, MPH
We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.
Guest: Julie A. Barta, MD, ATSF
Host: Peter J. Mazzone, MD, MPH, FCCP
Early detection of lung cancer is difficult, with many cases going undetected until it is too late. New methods using minimally invasive liquids biopsy and molecular biomarkers are in development to improve early detection of lung cancer. Join Dr. Peter Mazzone and Dr. Julie Barta as they discuss the latest data around two new blood-based assays with promising results for detecting lung cancer in high-risk individuals and the potential for improving patient survival.
Host: Paul Paik, MD
Guest: D. Ross Camidge, MD, PhD
Guest: Keith Kerr, BSc, MB ChB
Drs. Paul Paik, Keith Kerr, and Ross Camidge take us through testing considerations for MET exon 14 skipping mutations and optimal treatment approaches once a mutation is detected. They also discuss the emerging data and how to apply what we’re learning to everyday clinical practice.
Host: Alicia K. Morgans, MD, MPH
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Stacy Walker, NP
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Kelvin A. Moses, MD, PhD, FACS
Host: Alicia K. Morgans, MD, MPH
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Guest: Sarah Traverso, MMS, PA-C
In this eCourse tailored to advanced practice providers, get up to date on optimal care of metastatic CSPC, including management of treatment-related toxicities and key points for patient counseling.
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
Guest: Laura M. Spring, MD
Watch this educational activity to learn about the integration of novel agents into the treatment algorithm for patients with triple-negative breast cancer (TNBC) and current guideline-recommended strategies for the treatment and management of treatment-related adverse events in TNBC.
Guest: Sarah Tinsley-Vance, PhD, MSN, APRN-BC, AOCN
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
In this eCourse tailored to advanced practice providers, get up to date on optimal care of patients with myelodysplastic syndromes (MDS), including risk stratification, anemia management, and novel therapies.
Guest: Rasheda Persinger MSN, AGNP-C, AOCNP
Guest: Terran Sims, MSN, ACNP-C, CNN, COCN-C
In this activity, learn about the most recent recommendations for biomarker/molecular testing and personalized treatment plans for patients with non-small-cell lung cancer (NSCLC) based on results from testing.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Patrick Forde, M.B.B.Ch.
Host: Charu Aggarwal, MD, MPH
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Charu Aggarwal, MD, MPH
Host: Patrick Forde, M.B.B.Ch.
The treatment options for non-small cell lung cancer (NSCLC) are constantly evolving, making it challenging for healthcare professionals to stay updated with the latest scientific evidence. This program aims to address this challenge by bringing together esteemed faculty members who will discuss pivotal scientific advances and practice-altering information related to the use of systemic immunotherapy, targeted therapies, and perioperative immunotherapy in the management of NSCLC across all disease stages.
Host: Carlos M. de Castro, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Catherine Broome, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Carlos M. de Castro, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Carlos M. de Castro, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Catherine Broome, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Host: Catherine Broome, MD
This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.
Guest: Mary Weinstein Dunn
Watch this educational activity to learn about the latest guideline-recommended first-line and later-line treatments for advanced renal cell carcinoma (RCC), as well as strategies to manage adverse (AEs) events of novel therapies.
Host: Pavani Chalasani MD, MPH
Guest: Nick McAndrew, MD, MSCE
How can ribociclib plus endocrine therapy help reduce recurrence in early breast cancer? That’s the exact question the NATALEE trial sought to answer, and here to discuss the results with Dr. Pavani Chalasani is Dr. Nicholas McAndrew, Assistant Professor in the Division of Hematology and Oncology at the UCLA David Geffen School of Medicine.
Host: Jacob Sands, MD
Guest: Jia Luo, MD
NUT carcinoma is a rare, aggressive form of cancer that’s highly resistant to therapy and has no defined standard treatment. Joining Dr. Jacob Sands to discuss the best diagnostic and treatment strategies for NUT carcinoma is Dr. Jia Luo, medical oncologist at Dana-Farber Cancer Institute and an Instructor of Medicine at Harvard Medical School in Boston.
Host: Guy Young, MD
Hemophilia A is an inherited or spontaneously occurring secondary hemostasis disorder caused by clotting factor VIII deficiency, which affects the formation and stabilization of clots. If left untreated, hemophilia A can cause recurrent and disabling bleeding, leading to severe arthropathy or life- threatening hemorrhage. Prophylaxis is well-documented for its effectiveness in preventing arthropathy and life-threatening bleeds, and improving total bleeding rates. However, limitations of modern factor replacement treatment result in suboptimal outcomes, poor adherence to prophylactic regimens, and reduced QoL. Novel and emerging prophylactic therapies can mitigate some of the hindrances of traditional replacement therapy and enhance the overall effect of treatment in hemophilia A.
In this educational activity, expert faculty will review recent evidence from key clinical trials of prophylactic therapies that are expanding the armamentarium of therapeutic choices, including a novel high-sustained factor VIII replacement therapy, a bispecific antibody non-factor replacement therapy, and other emerging therapies. Evaluating patients’ goals and preferences will also be discussed, so clinicians can co-create treatment plans using a shared decision approach to improve adherence and reduce bleeding episodes in patients with hemophilia A.
Host: Pavani Chalasani MD, MPH
Guest: Colleen Bohnenkamp, PharmD, BCPS, BCOP
In a recent study, investigators conducted a randomized trial to compare the efficacy and tolerability of a fixed dose of an oral chemotherapy drug on a 7/7 schedule. Here with Dr. Pavani Chalasani to discuss the results from the X-7/7 trial is Dr. Colleen Bohnenkamp, Oncology Clinical Pharmacist who specializes in women’s cancers at the University of Kansas Cancer Center.
Host: Ryan Maves, MD
Guest: Kelly Pennington, MD
It’s estimated that respiratory syncytial virus (RSV) is responsible for up to 30 percent of viral respiratory infections in the stem cell transplant population. So how can we help RSV patients achieve their best outcomes? Learn more with Dr. Ryan Maves as he speaks with Dr. Kelly Pennington, Assistant Professor of Medicine at the Mayo Clinic in Rochester, Minnesota.
This program is produced in partnership with the American College of CHEST Physicians and is supported by an educational grant from GSK.
Host: Harry Paul Erba, MD, PhD
Guest: Courtney DiNardo, MD
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen as Drs. Harry Erba and Courtney DiNardo discuss advances in molecular profiling and classification of AML, as well as the newest approved treatments.
Host: Joseph Mikhael, MD
Guest: Monique Hartley-Brown, MD
Guest: Brandon Blue, MD
Multiple myeloma (MM) is the most common hematologic malignancy among African Americans, so it’s important that healthcare providers are aware of the disparities in the treatment provided to Black patients and White patients with MM. Listen in as Drs. Joseph Mikhael, Brandon Blue, and Monique Hartley-Brown discuss strategies to manage racial disparities and begin closing these gaps to ensure all patients receive the care they need.
Host: John L. Marshall, MD
Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairman’s Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI Cancer in Barcelona, Spain, so you can more effectively treat your patients.
Host: Petros Grivas, MD, PhD
Guest: Thomas Powles, MD, PhD
Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting, avelumab has become the global standard of care. Do you know how to evaluate and effectively implement immune therapy in the maintenance setting in your practice?
Guest: Tiffany Traina, MD, FASCO
Guest: Gregory Vidal, MD, PhD
Guest: Stephanie Walker, RN
Despite recent advances, triple-negative breast cancer (TNBC) remains difficult to treat due to a poor prognosis and a small number of effective treatments. Thus, clinicians’ priorities need to be aligned with patient goals and perspectives to ensure optimal care and overcome patient misunderstandings about treatment and clinical-trial options.
Join an expert panel of oncologists and oncology nurse practitioners for an in-depth discussion of patient-centered care practices for TNBC that incorporate and align with patient preferences for treatment. Panelists will also discuss effective strategies for TNBC management and the appropriate incorporation of novel therapies into treatment regimens.
Do you have patients who have been diagnosed with TNBC who could use education on treatment options, clinical trials, and available support resources? Direct your patients to MedLive.com to access the activity, “Navigating Treatment and Support for Triple-Negative Breast Cancer.”
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Gil Melmed, MD, MS
The inflammation biosimilar development process uses a stepwise approach with increasing certainty to generate the totality of evidence, which demonstrates the safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed.1,2 Dive further into the role of totality of evidence in the inflammation biosimilar development and approval process with Dr. Gil Melmed, Director of Inflammatory Bowel Disease Clinical Research at the Cedars-Sinai and Professor of Medicine at Cedars-Sinai and at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Melmed was compensated for participating in this program.
References:
-
US Food and Drug Administration. Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/135612/download
-
US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry. Published online April 2015. Accessed March 22, 2023. https://www.fda.gov/media/82647/download
©2023 Amgen Inc. All rights reserved. USA-CBU-81605 5/23
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Richard T. Penson, MD, MRCP
Uterine cancer is the most common type of gynecologic malignancy in the United States, and disease mortality is on the rise. What do we need to know from recent studies to diagnose patients earlier? Take a deep dive with Dr. Charles Turck as he is joined by Dr. Richard Penson, Medical Oncologist specializing in Gynecologic Oncology at Massachusetts General Hospital in Boston.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Richard Kim, MD
Guest: Benjamin A. Weinberg, MD
Sadly, colon cancer is a very common cause of cancer-associated death in the United States. However, things may be looking up as data from ongoing trials is uncovered. Explore metastatic colorectal cancer (mCRC) further with Dr. Charles Turck as he speaks with Dr. Richard Kim, Service Chief of Medical Gastrointestinal Oncology at Moffitt Cancer Center in Tampa, Florida, and Dr. Benjamin Weinberg, Associate Professor of Medicine and Attending Physician specializing in Gastrointestinal Medical Oncology and Sarcoma at MedStar Health in Washington, DC.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Priscilla Brastianos, MD
Brain metastases are the most common type of brain tumor, and unfortunately, prognosis is still limited and can range from a few months to a few years. However, the next-step approaches look promising for improving patient outcomes. Dive in with Dr. Charles Turck as he speaks with Dr. Priscilla Brastianos, Associate Professor of Medicine at Harvard Medical School and the Director of the Central Nervous System Metastasis Center at Massachusetts General Hospital.
In the US, the first-line treatment for metastatic colorectal cancer (mCRC) is chemotherapy with FOLFOX/FOLFIRI. However, a different combination treatment could show promise for being a first-line therapy selection. Learn more from this presentation of the data.
Since there are limited treatment options available for patients with refractory metastatic colorectal cancer (mCRC), the purpose of this global phase 3 cohort, called FRESCO-2, was to analyze the adverse events of a treatment. Tune into this segment to learn more about this study.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Frank Diehl, PhD
A poster presented at the 2022 American Association for Cancer Research Special Conference on Precision Prevention, Early Detection, and Interception of Cancer found that a four-biomarker class multi-cancer early detection (MCED) test configuration had higher overall sensitivity and specificity compared to a three-biomarker test configuration. These results imply that more early-stage cancers could be detected. Dive further into the data and results with Dr. Charles Turck and Dr. Frank Diehl, Senior Vice President of Multi-Cancer Early Detection at Exact Sciences Corporation and co-author of the poster.
This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.
Guest: Vivek Subbiah, MD
This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.
Host: Matthew J. Matasar, MD
Guest: Kami Maddocks, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: John P. Leonard, MD
Guest: Sarah Rutherford, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Kami Maddocks, MD
Guest: Matthew J. Matasar, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Sarah Rutherford, MD
Guest: John P. Leonard, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alex Herrera, MD
Guest: Alison J. Moskowitz, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alison J. Moskowitz, MD
Guest: Alex Herrera, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Alex Herrera, MD
Guest: Alison J. Moskowitz, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: John P. Leonard, MD
Guest: Sarah Rutherford, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Kami Maddocks, MD
Guest: Matthew J. Matasar, MD
This series of bite-sized episodes will provide important information in the evolving world of bispecific antibodies and antibody-drug conjugates for the treatment of lymphoma. Join our team of experts as they tackle the recent treatment advances in Hodgkin, follicular, and diffuse large B-cell lymphoma.
Since the recording of this program, on April 19, 2023, FDA approved polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for use in adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. To learn more about this approval, please visit: https://www.roche.com/media/releases/med-cor-2023-04-19
Host: Jason J. Luke, MD, FACP
Guest: Tara Mitchell, MD
The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.
Guest: Alison Wakoff Loren, MD, MSCE
Cancer occurs in approximately 1 in every 1,000 pregnant patients and requires complex solutions from a multidisciplinary team. Learn more about the expanding management options for these patients with Dr. Alison Loren, Chief of the Division of Hematology and Oncology at the University of Pennsylvania Perelman School of Medicine.
Host: Jacob Sands, MD
Guest: Joseph O. Jacobson, MD
Over the past few decades, increasing attention has been placed on reducing the risk of patient harm within the healthcare system. Learn more about the risks that are specific to medical oncology and how current systems are addressing them with Dr. Jacob Sands and Dr. Joseph Jacobson, Senior Advisor for Quality and Patient Safety at Dana-Farber Cancer Institute.
Host: Jacob Sands, MD
Guest: Aliyah Pabani, MD
Lung cancer patients undergoing immunotherapy may be at risk for developing life-threatening toxicities. Find out how you can manage them with Dr. Jacob Sands and Dr. Aliyah Pabani, Clinical Assistant Professor in the Department of Medicine at the University of Calgary and Director of the Alberta Immunotherapy Database.
Host: Jennifer Caudle, DO
Guest: Sara A. Hurvitz, MD, FACP
Guest: Narjust Florez, MD
This CME-accredited podcast explores the rationale for targeting human epidermal growth factor receptor 3 (HER3) in non–small cell lung cancer (NSCLC) and breast cancer. It includes an in-depth discussion of the mechanism of action, safety, and efficacy of agents that are being investigated to target HER3. The latest results from clinical trials investigating monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates targeting HER3 will also be discussed.
Host: Kara Kelly, MD
This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.
Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.
Host: Kara Kelly, MD
This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.
Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.
Host: Bradford Hoppe, MD, MPH
This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.
Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.
Host: Bradford Hoppe, MD, MPH
This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.
Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.
Host: Kara Kelly, MD
Guest: Bradford Hoppe, MD, MPH
This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.
Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jacob Sands, MD
Guest: Joshua K. Sabari, MD
Obstacles with platinum rechallenge could lead to treatment burden, but a second-line alternative therapy could be a better option for some of our patients. To learn more, Dr. Charles Turck is joined by Drs. Jacob Sands and Joshua Sabari to share their insights on this therapy for patients with small cell lung cancer.
Host: Helena Yu, MD
Guest: Makenzi Evangelist, MD
This Expert Exchange webcast is designed to enhance clinicians’ awareness of the function and role of HER3 in emerging treatment strategies for non-small cell lung cancer and metastatic breast cancer.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.
Host: Hope S. Rugo, MD, FASCO
Guest: Peter Schmid, FRCP, MD, PhD
HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationally for the treatment of HR+/HER2- early breast cancer, it’s important to keep up with the latest data for its use. Listen in so Drs. Hope Rugo and Peter Schmid can keep you up to date on the most effective ways to treat your patients.
Host: Mark Socinski, MD
Guest: Patrick Forde, M.B.B.Ch.
The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.
Host: Mark Socinski, MD
Guest: Patrick Forde, M.B.B.Ch.
The optimal management of non-small cell lung cancer (NSCLC) has fundamentally changed. Targeted agents, mono and combination immunotherapy, and immunochemotherapy options continue to emerge. You also need to factor in new and investigational neoadjuvant and adjuvant regimens. So how do you determine which patients will benefit most within this new landscape of options? Join Drs. Mark Socinski and Patrick Forde as they address these questions and provide a measure of order in the chaos.
Host: Hope S. Rugo, MD, FASCO
Guest: Peter Schmid, FRCP, MD, PhD
HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationally for the treatment of HR+/HER2- early breast cancer, it’s important to keep up with the latest data for its use. Listen in so Drs. Hope Rugo and Peter Schmid can keep you up to date on the most effective ways to treat your patients.
Guest: Michelle Mollica, PhD, MPH, RN, OCN
Can cancer survivorship models help clinicians navigate the road ahead with their cancer patients? Here to share insights on unmet needs, opportunities, and symptom burden for cancer survivorship care is Dr. Michelle Mollica, the Deputy Director at the National Cancer Institute’s Office of Cancer Survivorship.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hope S. Rugo, MD, FASCO
The treatment landscape for metastatic breast cancer is rapidly evolving. With all of these new advancements and research, it can be helpful to review the available treatment options and best practices for selecting an approach after treatment with a CDK4/6 inhibitor has failed. That’s why Dr. Charles Turck discusses how we can treat patients with metastatic breast cancer in the second- and third-line setting with Dr. Hope Rugo, who’s a Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco Hellen Diller Family Comprehensive Cancer Center.
Host: Fortunato Ciardiello, MD, PhD
Guest: Erika Martinelli, MD, PhD
Are you familiar with rechallenge strategies with anti-EGFR therapies to treat metastatic colorectal cancer? Listen as Drs. Fortunato Ciardiello and Erika Martinelli discuss patients most suitable for rechallenge with anti-EGFR therapies for metastatic colorectal cancer while outlining key clinical data.
Host: Julie E. Chang, MD
Bruton’s tyrosine kinase inhibitors (BTKi) have transformed treatment for people with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. Still, many patients discontinue treatment because of adverse events and treatment resistance. As science moves forward in understanding why some patients do not respond well to treatment with BTKi, a new generation of BTKi with a different mechanism of action (MOA) is emerging as a possible therapeutic alternative.
Now’s the time to learn about this promising new treatment path for CLL and MCL. In this activity, featuring four concise modules, an expert discusses the MOAs of covalent and non-covalent BTKi, current practices for using BTKi in treatment of CLL and MCL, the efficacy and safety data for novel BTKi, and the potential role of non-covalent BTKi in future treatment plans.
Host: Tanios S. Bekaii-Saab, MD
Guest: Joleen M. Hubbard, MD
Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer? Listen in as Drs. Tanios Bekii-Saab and Joleen Hubbard talk about the recent approval of tucatinib and trastuzumab for the treatment of HER2-positive metastatic CRC and other therapies in development.
Host: Barbara Burtness, MD
Guest: Nabil F. Saba, MD, FACP
KEYNOTE-048 has opened new vistas to managing patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Nonetheless, uncertainties remain in matching the correct patient with the correct strategy. Join Drs. Barbara Burtness and Nabil Saba as they parse the key trials and offer insight into building treatment algorithms designed to optimize outcomes for your patients with R/M HNSCC.
Host: Ezra Cohen, MD, FRCPSC, FASCO
Guest: Petr Szturz, MD, PhD
While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
While the state of cancer screening hasn’t seen too many changes over the years, the results from the PATHFINDER study may offer clinicians a new screening tool. Dr. Eric Klein from the Glickman Urological and Kidney Institute dives into this clinical data and how it might impact cancer screening protocols.
Host: Caron A. Jacobson, MD
Guest: Matthew Lunning, DO
Guest: Loretta J. Nastoupil, MD
Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now three approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
The educational activity features an expert roundtable panel discussion on real-world clinical practice experiences with CAR T-cell therapy for the treatment of diffuse large B-cell lymphoma (DLBCL) from the esteemed panelists, with a focus on the second-line setting. The faculty panel will evaluate the most recent clinical data and provide their expert insights on how new emerging evidence can and should be considered for real-world clinical practice. The discussion will also include a summary of second-line clinical trials, differentiation factors among …
Host: Caron A. Jacobson, MD
Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymphoma (LBCL) in the third or later line of therapy, there has been significant development in the field. There are now 3 approved CAR T-cell therapies for various subtypes of LBCL, and these immunotherapies are now moving into earlier treatment, with axi-cel and liso-cel both FDA approved in the second-line setting. At the same time, researchers have made tremendous strides in managing the hallmark toxicities of CAR T-cell therapy like cytokine release syndrome (CRS) and neurologic events, opening the possibility for this therapy to move safely beyond academic medical centers and into outpatient settings.
The educational activity features expert faculty evaluating the current treatment landscape of CAR T-cell therapy for relapsed/refractory LBCL, highlighting evidence set to transform clinical practice particularly in the second-line setting. A three-dimensional mechanism of action animation video clip will illustrate similarities and differences within the structure and costimulatory domains of different CAR T-cell therapies. This activity will serve as the foundation for a robust panel discussion activity entitled Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video …
Host: Jennifer Caudle, DO
Guest: Diane M. Harper, MD, MPH, MS
There are several testing methods available for cervical cancer screening, such as co-testing and primary HPV testing. So what are some of the most prominent benefits and limitations of these and other testing approaches? Joining Dr. Jennifer Caudle to break down the latest advancements in cervical cancer screening is Dr. Diane Harper, a Professor in the Departments of Family Medicine and Obstetrics and Gynecology at the University of Michigan.
Host: Jennifer Caudle, DO
Guest: Majed Refaai, MD
While VKA-related GI bleeds are common, clinicians need to be aware of the severity of the bleed, especially in cases of hemodynamic instability. To get a better understanding of the impact of this severity, Dr. Majed Refaai from the University of Rochester Medical Center shares insights on these life-threatening bleeds.
Guest: Narjust Duma, MD
Guest: David J. Feller-Kopman, MD
Guest: Bruce E. Johnson, MD
Guest: Razelle Kurzrock, MD, FACP
Guest: Ignacio Wistuba, MD
Lung cancer incidence is decreasing due in part to reduced smoking rates, and new trends are emerging as things change. But despite these advancements, some challenges remain to be solved. Explore those challenges and key strategies for overcoming them in this four-part series.
PP-US-8201a-1520 12/22
Host: Thomas F. Patterson, MD, FACP, FIDSA
Guest: George Thompson III, MD, FIDSA
The changing epidemiology of invasive fungal infections, ongoing antifungal resistance, drug-drug interactions, and few oral agents leave patients with limited viable treatment options. While the antifungal pipeline has been essentially dry for the past 2 decades, several antifungal drugs are now in late-stage clinical development and poised to address these unmet needs. But take heed: They will need to be treated as precious commodities lest they, too, become ineffective due to resistance.
For patients with ER+/HER2- advanced breast cancer, current treatment guidelines recommend the use of endocrine therapy plus a CDK 4/6 inhibitor as a first-line treatment. And while the guidelines recommend sequential endocrine therapy for disease progressions, this progression can lead to ESR1 mutations and resistance to endocrine therapy. Could a novel oral selective estrogen receptor have more efficacy in preventing ESR1 mutations associated with endocrine resistance? That’s the exact question the EMERALD trial sought to answer, and what this study found in its subgroup analyses is the focus of this Audio Abstract.
Host: Jennifer Caudle, DO
Guest: Nan Chen, MD
Selective estrogen receptor degraders (SERDs) are a novel class of drugs for the treatment of ER+/HER2- advanced breast cancer. So how exactly do they work to treat this type of advanced breast cancer, and what are the findings from recent trials investigating the clinical utility of SERDs? Get the answers to these and other key questions with Dr. Jennifer Caudle and Dr. Nan Chen, Assistant Professor of Medicine at the University of Chicago School of Medicine.
Host: Jennifer Caudle, DO
Guest: Stephanie Graff, MD
Endocrine resistance and toxicities are just a few of the many challenges facing clinicians who treat patients with ER+/HER2- advanced breast cancer. So what strategies can we use to better address these challenges and unmet needs? Joining Dr. Jennifer Caudle to share her approach is Dr. Stephanie Graff, Director of the Breast Oncology Program at Lifespan Cancer Institute in Providence, Rhode Island.
Endocrine therapy is the recommended treatment for ER+/HER2- advanced breast cancer, but progression to advanced disease can lead to ESR1 mutations, which can then lead to endocrine therapy resistance. But could treatment with an oral selective estrogen receptor degrader (SERD) improve outcomes for our patients? Join us as we take a deep dive into the EMERALD trial, which explored that exact question, in this Audio Abstract.
Host: Jennifer Caudle, DO
Guest: Stephanie Graff, MD
Guest: Pavani Chalasani MD, MPH
Given the challenges and unmet needs associated with the current treatment options for ER+/HER2- advanced breast cancer, what strategies can we use to optimize our approach? Here with Dr. Jennifer Caudle to share their perspectives are Dr. Stephania Graff from Lifespan Cancer Institute and Dr. Pavani Chalasani from the University of Arizona Cancer Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Mascarenhas, MD
Guest: Raajit Rampal, MD, PhD
What do we need to know about the therapeutic landscape and management of myelofibrosis-related anemia? Here to share their perspectives with Dr. Charles Turk are Dr. Raajit Rampal from the Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai.
Host: Wui-Jin Koh, MD
Join our top experts from around the world as they discuss evidence- and consensus-based recommendations from The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), as well as the latest emerging clinical evidence in the optimal treatment of cancer. This multi-format, multispecialty, and multiregional educational initiative is designed to support your knowledge, competence, and skills across multiple solid tumor types.
Host: Jennifer Caudle, DO
Guest: Roy Rosin, MBA
Guest: Shivan Mehta, MD, MBA, MSHP
From home care to cancer screening, what are some of the top initiatives in patient care at Penn Medicine’s new Acceleration Lab? Mr. Roy Rosin and Dr. Shivan Mehta sit down with Dr. Jennifer Caudle to share the latest updates from the Acceleration Lab.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Clifford Takemoto, MD
With so many potential therapies emerging for sickle cell disease, where are we with the treatment of adults and children? Dr. Charles Turck joins Dr. Clifford Takemoto, the Chief of the Clinical Division of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, to share therapeutic updates from the 64th Annual American Society of Hematology Meeting.
Host: Aaron Gerds, MD
There are two key unmet needs in the treatment of myelofibrosis. Here to share what those are and how we can work to address them is Dr. Aaron Gerds from the Cleveland Clinic.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Mascarenhas, MD
There are several challenges and limitations associated with the current therapeutic options available for myelofibrosis-related anemia, leading to a recent push to transform the treatment paradigm. Joining Dr. Charles Turck to share strategies for optimizing the care of patients with myelofibrosis-related anemia is Dr. John Mascarenhas, Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Mount Sinai Tisch Cancer Center.
Host: William J. Gradishar, MD
Guest: Javier Cortes, MD, PhD
Guest: Hope S. Rugo, MD
New data for sequencing antibody-drug conjugates (ADCs) in HER2 metastatic breast cancer have hit the conference circuit. Listen as Drs. William Gradishar, Javier Cortés, and Hope Rugo dissect the data surrounding ADCs in different types of HER2 metastatic breast cancer. Make sure you’re up to date and offering your patients the best care.
HPV testing plays an important role in cervical cancer screening, but not every patient whose HPV-positive will develop cervical cancer. One option that can help us identify which HPV-positive patients are truly at risk is CINtec PLUS Cytology, an immunohistochemistry test that simultaneously detects p16 and Ki67 biomarker proteins. Learn more about how this dual staining technique works in this video.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Patients with acute myeloid leukemia (AML) are at high risk for febrile neutropenia or profound, protracted neutropenia. So how can we monitor for the risk of neutropenia in AML patients starting venetoclax therapy? That’s what Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute, is here to explain.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understanding of the AML genomic landscape, it’s become possible to further the development of AML therapies. Joining Dr. Charles Turck to explore venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Guest: Ilene Galinsky BSN,MSN,ANP-C
Here to review the ramp-up and dosing for venetoclax therapy in patients with newly diagnosed acute myeloid leukemia is Ilene Galinsky, Senior Program Research Nurse Practitioner for the Leukemia Program at Dana Farber Cancer Institute.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
No matter whether you’re using venetoclax for chronic lymphocytic leukemia in the first-line or relapsed/refractory setting, there are some important considerations to keep in mind, like its dose ramp-up as well as the importance of hydration and tumor lysis syndrome prophylaxis. Tune in as Dr. Lisa Nodzon, advanced oncology certified nurse practitioner in the Department of Malignant Hematology at Moffitt Cancer Center, reviews those key considerations and more.
Guest: Lisa Nodzon PhD, ARNP, AOCNP
Both the disease itself and the treatments for chronic lymphocytic leukemia (CLL) can cause neutropenia, which is why Dr. Lisa Nodzon from the Moffitt Cancer Center is here to discuss neutropenia in relation to CLL treatment with venetoclax.
Host: Jacob Sands, MD
Guest: Tomasz Beer, MD, FACP
Multi-cancer early detection tests are designed to detect multiple cancers from a single blood test. Could these tests help address some of the most common limitations associated with current cancer screening methods, like a lack of adherence and access? Joining Dr. Jacob Sands to discuss how multi-cancer early detection tests work and their potential impact on cancer screening is Dr. Tom Beer, Adjunct Professor of Medicine at the OHSU Knight Cancer Institute and the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Namrata Chandhok, MD
Underrepresentation is widespread in hematological clinical trials. To learn more about the challenges preventing representation—and possible solutions—Dr. Charles Turck joins Dr. Namrata Chandhok from the Sylvester Comprehensive Cancer Center at the University of Miami to share insights on inclusion in clinical trials from the American Society of Hematology annual Meeting.
Host: Richard S. Finn, MD
Guest: Peter R. Galle, MD
Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?
Host: Kevin J. Harrington, MBBS, PhD
Guest: Barbara Burtness, MD
Guest: Ari Rosenberg, MD
There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Aasma Shaukat, MD, MPH
Adenoma detection rate (ADR) may help us better detect our patients’ risk of developing colorectal cancer. To explore what we need to know about this quality indicator, Dr. Peter Buch joins Dr. Aasma Shaukat from the New York University Grossman School of Medicine to talk about ADR.
Host: Benjamin Levy, MD
Guest: Rebecca Heist, MD, MPH
Guest: Peter Bela Illei, MD
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
Host: Benjamin Levy, MD
Guest: Rebecca Heist, MD, MPH
Guest: Peter Bela Illei, MD
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
Host: Aparna R. Parikh, MD
Guest: Dustin Deming, MD
Guest: Scott Kopetz, MD, PhD
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
Host: Aparna R. Parikh, MD
Guest: Dustin Deming, MD
Guest: Scott Kopetz, MD, PhD
In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
Host: Jyoti D. Patel, MD, FASCO
Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
Host: Jyoti D. Patel, MD, FASCO
Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
Host: Paul Paik, MD
Guest: Catherine Shu, MD
Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
Host: Paul Paik, MD
Guest: Catherine Shu, MD
Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
Guest: Patrick Forde, MD
Guest: Jesús García-Foncillas, MD, PHD
Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!
Guest: Patrick Forde, MD
Guest: Jesús García-Foncillas, MD, PHD
Immune checkpoint inhibitors, or ICIs, have improved the prognosis for patients with many different types of cancer. Drs. Forde and García-Foncillas outline current biomarkers and the importance of testing to optimize patient outcomes. Your patients will thank you for tuning in!
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: A. Mark Fendrick, MD
With the relaunch of the Cancer Moonshot initiative, implementing strategies to overcome disparities in cancer screening is critical to reducing the rate of cancer mortality. Dr. Charles Turck joins Dr. Mark Fendrick to explore these disparities, and discuss the role of multicancer detection tests.
Host: Pavani Chalasani MD, MPH
Guest: Hope S. Rugo, MD
Results from the TROPiCS-02 trial may impact survival for patients with receptor–positive/HER2-negative breast cancer. To find out why, Dr. Hope Rugo from the University of California San Francisco Comprehensive Cancer Center joins Dr. Pavani Chalasani to talk about the study and how it might impact the future of breast cancer treatment.
Host: Janani Reisenauer, MD
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Lung cancer screenings have shown to be effective in detecting lung cancer earlier. So what are the current guidelines? To discuss this question and give their own experiences with lung cancer screenings and the management of early-stage lung cancer are expert pulmonologists, Drs. Septimiu Murgu and Janani Reisenauer. Dr. Murgu is from the University of Chicago, and Dr. Reisenauer is from the Mayo Clinic.
Host: Jacob Sands, MD
Guest: Edward B. Garon, MD, MS
Recently approved capmatinib may be a new treatment for patients with metastatic non-small cell lung cancer who have MET exon 14 skipping mutations. To learn more about this emerging treatment option, Dr. Jacob Sands speaks with Dr. Edward Garon from the David Geffen School of Medicine at the University of California in Los Angeles to explore data from the GEOMETRY Mono-1 study.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sean Lawler, PhD
The STING protein is a novel treatment pathway for cancer. How might it affect our patients’ immune response to diseases such as brain cancer? Dr. Sean Lawler, an Associate Professor in the Department of Pathology and Laboratory Medicine at Brown University in Providence, Rhode Island. joins Dr. Andrew Wilner to explore the role of the STING pathway.
Host: Courtney DiNardo, MD
Guest: Marina Y. Konopleva, MD, PhD
Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.
Host: Courtney DiNardo, MD
Guest: Marina Y. Konopleva, MD, PhD
Developments over the last few years have brought dramatic changes to the treatment landscape of acute myeloid leukemia (AML). While new therapies mean more opportunities to individualize care, clinicians are also faced with new challenges and must quickly evaluate patients, order appropriate molecular tests, assess risk, and differentiate the efficacy, safety, and applicability of novel treatments and combinations. Join Drs. Courtney DiNardo and Marina Konopleva for a discussion of how to untangle the data to determine which treatment is right for each patient in the increasingly complex clinical setting of AML.
Guest: Benjamin Izar, MD
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Brain metastases are common in patients with advanced melanoma and are a leading cause of cancer-related death. However, little is known as to why melanoma spreads to the brain, but new research from Columbia University may provide some answers. To discuss this recent discovery, Dr. Andrew Wilner is joined by Dr. Benjamin Izar, Assistant Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Ehab L. Atallah, MD
New longer-term outcome data for chronic lymphocytic leukemia (CLL) has recently emerged with some interesting results. To dive into the key findings of these trials and other current CLL treatments available, Dr. Charles Turck is joined by Dr. Ehan Atallah, Professor of Medicine and the Section Head of Hematological Malignancies at the Medical College of Wisconsin Division of Hematology and Oncology.
Guest: Rishi D. Naik, MD, MSCI
Colorectal cancer may be more prevalent than you think, underscoring the importance of colorectal cancer screening. Join us as we explore the latest screening recommendations and available modalities with Dr. Rishi Naik, Assistant Professor of Medicine in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: Guillermo Garcia-Manero, MD
Guest: Rami Komrokji, MD
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
Host: Guillermo Garcia-Manero, MD
Guest: Rami Komrokji, MD
Lower-risk MDS is an acquired bone marrow disorder that manifests with symptomatic anemia. Over time, many of these patients become dependent on red cell transfusions. Erythropoiesis-stimulating agents (ESAs) are first-line treatment, but not all lower-risk MDS patients respond to ESA and many eventually become refractory to ESAs. Join Drs. Guillermo Garcia-Manero and Rami Komrokji as they discuss the diagnostic and prognostic imperatives associated with lower-risk MDS, when to initiate and move on from ESA therapy, and an approach for patients in whom ESAs are no longer effective.
Host: John J. Russell, MD
Guest: John P. Cooke, MD, PhD
mRNA was first discovered in the 1980s, and it wasn’t until recently that mRNA technology entered the spotlight. But how did we get to this point, and where do we go from here? Discover this and more with Dr. John Russell and Dr. John Cooke, Director of the Center for Cardiovascular Regeneration and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.
Guest: John P. Cooke, MD, PhD
Message RNA (mRNA) is a copy of a gene within DNA. And based on how mRNA functions in the body, how can we leverage it to help protect us against infectious disease? Explore this and more with Dr. John P. Cooke, Director of the Center for Cardiovascular Regeneration and Medical Director of the RNA Therapeutics Program in the Houston Methodist DeBakey Heart and Vascular Center.
Host: Ayse Tuba Kendi, MD
Guest: A. Oliver Sartor, MD
Prostate cancer–specific antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).
In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Julie Blatt, MD
Guest: Taizo Nakano, MD
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Julie Blatt, MD
Guest: Taizo Nakano, MD
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
Host: Pavani Chalasani MD, MPH
Guest: Prof. David Cameron
A groundbreaking clinical study on patients with HER2-low breast cancer may impact they way we provide treatment. Dr. David Cameron from the University of Edinburgh in Scotland joins Dr. Pavanai Chalasani to share key results from the DESTINY Breast04 trial.
Host: Shanu Modi, MD
Guest: Sara A. Hurvitz, MD, FACP
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment strategies for patients with HER2+ breast cancer.
Host: Shanu Modi, MD
This Clinical Case Challenge is designed to help improve clinical decision making for providers caring for patients with HER2+ breast cancer.
Host: Pavani Chalasani MD, MPH
Guest: Erika Hamilton, MD
A new treatment option for breast cancer may alter the treatment landscape for patients with HER2-positive metastatic breast cancer. Joining Dr. Pavani Chalasani to share data from the DESTINY Breast03 trial is Dr. Bethany Hamilton, the Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon Research Institute at Tennessee Oncology.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Janani Reisenauer, MD
Guest: Colleen Channick, MD, FCCP, DAABIP
A multidisciplinary panel including a medical oncologist, a thoracic surgeon, and an interventional pulmonologist will discuss the role of lung cancer teams in their thoracic oncology practices. The panelists will review their management of patients with lung cancer during the COVID-19 pandemic, including the impact of delayed procedures and telemedicine on patient outcomes.
Host: Mark Socinski, MD
Guest: Jennifer Marie Suga, MD, MPH
There are new targeted therapies that are now approved for the treatment of advanced non-small cell lung cancer. Dr. Mark Socinski & Dr. Marie Suga discuss evolving diagnostic approaches and best practices for selecting the right therapy for patients with NSCLC.
Host: Pavani Chalasani MD, MPH
Guest: Kevin Kalinsky MD, MS
CDK4/6 inhibitors have changed the treatment landscape for hormone receptor-positive/HER2-negative metastatic breast cancer. But if the disease progresses, should we switch our patients to endocrine therapy? Joining Dr. Pavanai Chalasani to answer this question and share the most recent research from the MAINTAIN trial is lead researcher, Dr. Kevin Kalinsky from the Winship Cancer Institute at Emory University.
Host: Monique Hartley-Brown, MD, MMSc
Guest: Shonali Midha, MD
Significant progress has been made with induction and initial treatment of multiple myeloma, leading to longer and deeper remissions for patients. Yet, how do you decide which regimen is best? Hear how Dr. Monique Hartley-Brown and Dr. Shonali Midha navigate the treatment of their newly diagnosed patients and what factors they consider when selecting a regimen.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Narjust Duma, MD
Guest: Andreas Rimner, MD
Two internationally known medical and radiation oncologists will discuss ongoing and recent clinical trials and offer their perspectives on how they will impact thoracic oncology practice. The panelists will also discuss current guidelines for managing patients with advanced lung cancer and emphasize the role of tissue and blood biomarkers.
Host: Jacob D. Soumerai, MD
Guest: Andrew H. Lipsky, MD
The landscape of treatment for CLL is rapidly evolving, with promising results from trials examining chemotherapy-free regimens in the frontline setting. While these targeted approaches utilizing BTK or BCL-2 inhibitors have largely displaced chemoimmunotherapy in frontline management of CLL, there remains a clinically significant fraction of patients who will require subsequent therapy after developing drug intolerance or progressive disease. Join Drs. Andrew Lipsky and Jacob Soumerai as they strategize which targeted therapeutic options for relapsed/refractory CLL likely offer each individual patient the safest and most effective clinical outcome.
Host: Ian W. Flinn, MD, PhD
Guest: William Wierda, MD
Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent’s unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.
Host: Susan O’Brien, MD
Guest: Timothy Call, MD
The process of matching the most optimal first-line therapy to patients with CLL has recently undergone a paradigm shift. Along with a widening focus on targeted agents, untangling key patient- and disease-centric parameters adds complexity to this shared decision. Join Drs. Susan O’Brien and Timothy Call as they offer clarity to this first-line decision process—a clarity that you can readily take into the clinic.
Host: Shaji K. Kumar, MD
Guest: María-Victoria Mateos, MD, PhD
A plethora of new data for multiple myeloma were presented at ASCO 2022. Hear Dr. Shaji Kuman and Dr. Maria-Victoria Mateos discuss the most relevant findings and which emerging strategies look promising for patients.
Guest: Amrita Krishnan, MD
Guest: Morie Gertz, MD, MACP
Patients with multiple myeloma inevitably experience disease relapse, which is challenging. Rapid therapeutic advances have heralded an increasing number of efficacious targeted strategies and combination therapies for patients after a first relapse or in those with heavily pretreated disease. However, selecting the optimal regimen requires a individualized approach. Hear how Dr. Amrita Krishnan and Dr. Morie Gertz translate the evolving clinical data into their clinical practices and what factors influence their choices to improve durable responses and outcomes for patients with relapsed/refractory multiple myeloma.
Guest: Amrita Krishnan, MD
Guest: Cesar Rodriquez Valdes, MD
There is an unmet clinical need for more durable responses in patients with multiple myeloma because of their inevitable relapses. Advances in our ability to delineate the molecular pathobiology of the disease are guiding impressive new therapeutic options for this patient population. Join Dr. Cesar Rodriguez Valdes and Dr. Amrita Krishnan as they discuss the latest data around emerging agents targeting BCL-2 and BCMA for multiple myeloma and the investigational targets on the horizon.
Guest: Caitlin Costello, MD
Guest: Ravi Vij, MD
Frontline management of patients with newly diagnosed multiple myeloma is complicated by a multitude of current and newer agents, and navigating the guidelines can be confusing. Tune in as Drs. Caitlin Costello and Ravi Vij provide insight into the newer agents and different administration modalities so that you can address your patients’ questions.
Host: Pavani Chalasani MD, MPH
Guest: Seema A. Khan, MD
Dr. Pavani Chalasani meets with Dr. Seema Khan, a Professor of Surgery and Interim Co-Vice Chair of Research at Northwestern Feinberg School of Medicine, to explore the role of surgery in metastatic breast cancer and take a look at the current treatment landscape.
Host: Jacob Sands, MD
Guest: Maya Leiva, PharmD, BCOP
What causes drug shortages in the U.S.? Joining Dr. Jacob Sands to answer this question and dive in to what physicians and pharmacists can do to prepare for future shortages is Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.
Host: Jacob Sands, MD
Guest: Maya Leiva, PharmD, BCOP
Recognizing bias and improving diversity is critical for patient outcomes, especially within the field of oncology. To explore how we can improve care for both LGBTQ+ patients and employees within healthcare, Dr. Jacob Sands is joined by Dr. Maya Leiva, an Associate Professor of Pharmacy Practice at West Coast University and a board certified board certified hematology and oncology clinical pharmacy specialist at Inova Schar Cancer Institute.
HER2 (ERBB2) mutations may increase receptor internalization and lead to hyperactive downstream signaling, uncontrolled cell growth, and tumorigenesis. Learn more about how HER2 mutations affect several types of cancer, including non-small cell lung cancer (NSCLC).
Intended for US Healthcare Professions only
©2022 Daiichi Sankyo, Inc. and AstraZeneca. PP-US-8201a-1332 06/22
Host: Eric Edell, MD, FCCP
Host: Septimiu Murgu, MD, FCCP
Guest: Narjust Duma, MD
Guest: Christopher Hartley, MD
Guest: Jeffrey Mueller, DO
Expert pathologists and a medical oncologist will discuss current guidelines and their own practices regarding the role of liquid biopsy and comprehensive genetic and PD-L1 testing in the management of advanced lung cancer. The panelists will also explore various strategies for optimizing the quantity and quality of cytology and small volume biopsy specimens.
Host: Luis Paz-Ares, MD, PhD
Guest: Kristen Marrone, MD
In the first-line management of non-small cell lung cancer, the use of immune checkpoint inhibitors (ICI) as monotherapy, as dual ICI, in combination with chemotherapy, or not at all is broadly dependent on which biomarkers are identified. While the choice of therapy is generally based on the level of expression of 1 or more biomarkers (eg, PD-L1, TMB), other factors often complicate this decision. Join us as Drs. Luis Paz-Ares and Kristen Marrone tackle these complexities by providing both foundational and clinical guidance to help you help your patients.
Host: Elizabeth Smyth, MD
Guest: Jaffer Ajani, MD
HER2 expression is a crucial biomarker when selecting treatment for patients with advanced gastric and gastroesophageal junction (GEJ) cancers. Until recently, there were limited therapeutic options. Join this lively conversation to enhance your knowledge related to emerging data and optimal treatment selection for patients with HER2-positive gastric and GEJ cancers.
Host: Septimiu Murgu, MD, FCCP
Host: Eric Edell, MD, FCCP
Guest: Nichole Tanner, MD, MS, FCCP
Guest: Fabien Maldonado, MD, FCCP
Two internationally known interventional pulmonologists will discuss current guidelines and their own experiences regarding sampling of lung lesions and mediastinal adenopathy. Specifically, the panelists will discuss the pros and cons of various diagnostic strategies and sampling techniques, including transcutaneous and bronchoscopic biopsies. This interactive webinar will offer the opportunity for learners to ask questions prior to and during the event. Learning is augmented by a few follow-up quizzes weeks after the webinar, a strategy proven to improve knowledge gain and retention.
Host: Pavani Chalasani MD, MPH
Guest: Kevin Kalinsky MD, MS
Chemotherapy is one of the most commonly used treatments for cancer—but it can lead to challenging side effects. So do all of our patients really need it? Joining Dr. Pavani Chalasani to discuss whether or not chemotherapy is the right choice for patients with hormone receptor-positive HER2-negative, node-positive breast cancer is Dr. Kevin Kalinsky from Emory University.
Host: Jacob Sands, MD
Guest: Marie Wood, MD
Can our breast cancer patients benefit from chemoprevention? Joining Dr. Jacob Sands to share treatment options for chemoprevention and which patients may benefit the most is Dr. Marie Wood, the Director of Breast Medical Oncology and Director of the Cancer Clinical Trials Office at the University of Colorado Anschutz Medical Center.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Sagar Lonial, MD
Guest: Noopur Raje, MD
Two newly approved BCMA-directed CAR T cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are providing patients with the prospect of deep and durable remissions. Maximizing the potential of CAR T cell therapy can provide improved length and quality of life for patients with multiply relapsed multiple myeloma. Join us as Dr. Sagar Lonial and Dr. Noopur Raje discuss the available treatment options, current applications of the clinical data, and strategies to improve care for your patients with multiple myeloma who may be candidates for CAR T cell therapy.
Host: Lyudmila Bazhenova, MD
Guest: Benjamin Levy, MD
HER2-targeted therapies have demonstrated substantial survival benefits for patients with HER2-positive breast cancer. So can we use those agents for HER2-positive NSCLC? Join Dr. Lyudmila Bazhenova and Dr. Benjamin Levy as they discuss the latest data around emerging agents for HER2-positive NSCLC and the best way to identify these mutations in clinical practice.
Host: Anthony Mato, MD, MSCE
During the past 10 years, BTK inhibitors are increasingly replacing chemotherapy-based regimens, especially in patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Current clinical practice is continuous long-term administration of covalent, irreversible BTK inhibitors, which can be complicated by side effects or the development of drug resistance. Resistance mutations and intolerance contribute to therapy interruption or discontinuation and abrogate clinical benefits associated with continued covalent BTK inhibitor therapy, leading to subsequent care that is suboptimal due to a dearth of effective treatment options (as reflected in lower progression-free survival, overall survival, or response duration). Non-covalent, reversible BTK inhibitors do not bind to C481, therefore providing a potentially effective option to patients with B cell malignancies that have developed resistance to covalent BTK inhibitors. Preliminary clinical studies have suggested that non-covalent BTK inhibitors are effective and well-tolerated.
This educational activity will assist hematology-oncology professionals develop management plans designed to overcome these challenges and offer patients the full benefit of BTK inhibitor therapy. We will discuss the clinical implications of BTK inhibitor selectivity profiles and safety differences; the integration of BTK inhibitors into the management of different B-cell cancer patient populations; and the proactive adaptation of treatment plans to …
Host: Amer Zeidan, MBBS
Guest: Amy E. DeZern, MD, MHS
MDS is a very heterogenous clonal bone marrow disorder with a high risk for anemia and progression into acute myeloid leukemia. Dr. Amer Zeidan and Dr. Amy DeZern discuss how to appropriately monitor and treat patients with higher-risk MDS.
Host: Andrew M. Brunner, MD
Guest: Amy E. DeZern, MD, MHS
New and novel therapeutics for the treatment myelodysplastic syndrome (MDS) are in development. What are these agents, and how do they work? Listen in as Dr. Andrew Brunner and Dr. Amy DeZern discuss ongoing clinical trials, current data from those trials, and the future potential for tailoring treatment plans.
Since the completion of this activity, the U.S. Food and Drug Administration has lifted the partial clinical hold placed on studies evaluating the investigational agent magrolimab in combination with azacytidine for the treatment of MDS and AML.
https://clinicaltrials.gov/ct2/results?cond=&term=Magrolimab+&cntry=&state=&city=&dist=
Host: Larry Anderson, MD, PhD
Guest: Thomas G. Martin, MD
Patients with multiple myeloma (MM) whose disease has relapsed multiple times have historically poor outcomes. CAR T cell therapy is a novel therapeutic option for those patients and can provide prolonged responses and improved outcomes. However, the treatment is complex, and careful planning is needed to effectively incorporate these treatments into practice. Drs. Thomas Martin and Larry Anderson discuss CAR T cell therapies for MM with a focus on patient selection, accessibility of treatment, and management of patients after administration.
Host: Heather Wakelee, MD, FASCO
Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC.
This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.
Host: Fuad El Rassi, MD
A common complication of sickle cell disease (SCD), vaso-occlusive crisis (VOC), is characterized by the sudden onset of severe pain and is the most common reason for hospital visits in patients with SCD. Vaso-occlusion is caused by the adhesion of sickled erythrocytes and leukocytes to the endothelium, resulting in vascular obstruction and tissue ischemia. In addition to severe pain, long-term complications of vaso-occlusion may include damage to muscle and/or bone, in addition to vital organs such as the liver, spleen, kidneys, and brain. Vaso-occlusion and VOCs are associated with decreased organ function and can result in life-threatening complications such as acute chest syndrome, pulmonary hypertension, renal failure, and stroke. SCD can also have a profound effect on the quality of life for children and adults.
With increased understanding of the pathophysiology of VOCs, novel therapies that target the pathologic process of vaso-occlusion may reduce cell adhesion and inflammation, leading to decreased incidence of VOCs and prevention of end-organ damage. This educational activity will review the burden of SCD, including VOCs, acute chest syndrome, and end-organ damage in adults and pediatric sickle cell patients, as well as efficacy and safety data of established and novel therapies that target SCD-related complications for …
Host: Jacqueline Garcia, MD
Guest: David A. Sallman, MD
In order to effectively treat the MDS patient in front of us, we first need to classify their disease and understand its risk stratification category. Hear what Dr. David Sallman and Dr. Jacqueline Garcia have to say about MDS prognosis and risk stratification to better understand each patient’s disease progression.
Host: Jacob Sands, MD
Guest: Manish A. Shah, MD FASCO
For patients with unresectable liver-limited hepatocellular carcinoma, treatment can be challenging. Clinicians typically care for these patients with local-regional therapies, but is that the best option for all of them? To answer this question, Dr. Jacob Sands joins Dr. Manish Shah from Weill Cornell Medicine to take a look at current and emerging strategies for managing and treating unresectable liver-limited hepatocellular carcinoma.
Host: Jacob Sands, MD
Guest: Edith Mitchell, MD, MACP, FCPP, FRCP
Appointed member to the President's Cancer Panel and Clinical Professor of Medicine at Thomas Jefferson University, Dr. Edith Mitchell, shares what the panel recommends to close gaps in cancer screening in the U.S.—with a focus on colorectal cancer—to improve access for all patients.
Host: Jennifer Caudle, DO
Guest: Leonard A Valentino, MD
Unfortunately, recognizing and diagnosing patients with bleeding disorders is only the first of many challenges. Once a diagnosis is reached, patients may face a variety of chronic health challenges and even altered family dynamics. Fortunately, recent treatments and developments—and even those on the horizon—can help alleviate the burden of bleeding disorders on patients and their loved ones. Join Dr. Jennifer Caudle as she uncovers those important efforts with Dr. Leonard Valentino, President and Chief Executive Officer at the National Hemophilia Foundation.
Host: Neilanjan Nandi, MD
Guest: Samir Shah, MD
From new guideline recommendations to a concert featuring the American College of Gastroenterology’s official band, a lot is being done to help raise awareness of the importance of screening for colorectal cancer. So how can you help increase screening rates in your own community? Get inspired with these creative initiatives shared by Dr. Neil Nandi and Dr. Samir Shah, President of the American College of Gastroenterology.
Host: Scott Kopetz, MD, PhD
Guest: Elena Elez, MD, PhD
Guest: Elizabeth Smyth, MD
Even with the recent advances in therapeutic options for patients with BRAF V600E-mutated metastatic colorectal cancer (mCRC), they still have an uphill climb ahead of them.
How will the new standard of care in the second-line setting address global challenges and unmet needs regarding molecular profiling and treatment sequencing options?
Join us as 3 experts, Dr. Scott Kopetz, Dr. Elizabeth Smyth, and Dr. Elena Elez, untangle these new advances in treatment and offer their insights on how diagnostic testing can improve patient outcomes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Maryam Lustberg, MD, MPH
Amid the evolving treatment landscape for HER2-low breast cancer, many therapeutic challenges and limitations remain, resulting in unmet needs for our patients. Fortunately, developments in the therapeutic landscape can help address those unmet needs, and joining Dr. Charles Turck to share what’s on the horizon is Dr. Maryam Lustberg.
Host: Jacob Sands, MD
Guest: Kathleen Fenn, MD
Guest: Oudai Hassan, MD
How do the 2018 ASCO/CAP guidelines redefine our approach to caring for patients with HER2-mutated breast cancer? Find out as Dr. Jacob Sands speaks with Dr. Kathleen Fenn and Dr. Oudai Hassan about HER2 scoring criteria and how the data drives collaborative care between the medical oncology and pathology teams.
Guest: Pavani Chalasani MD, MPH
What were the key findings from the EMERALD, Destiny-03, and PADA 1 trials that were featured at the 2021 San Antonio Breast Cancer Symposium? Explore the data on emerging breast cancer therapies with Dr. Pavani Chalasani, Associate Professor of Medicine and Program Director of the Hematology and Oncology Fellowship at the University of Arizona Cancer Center.
Host: Kristen Whitaker, MD, MS
Guest: Ricki Fairley, BA, MBA
Guest: Sara M. Tolaney, MD, MPH
For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States.
This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.
Guest: S. Michelle Shiller, DO, AP/CP, MGP
Guest: John V. Heymach, MD, PhD
Exon 20 insertion mutations account for up to 10 percent of EGFR mutations and approximately 2 percent of all non-small cell lung cancer mutations. Although less common, EGFR mutations at exon 20 have an important impact on therapy selection. That’s why Dr. John Heymach speaks with Dr. Michelle Shiller about what those impacts are as well as the available therapies for patients with these mutations.
All trademarks are the property of their respective owners.
Host: Miguel A. Escobar, MD
Guest: Cindy Leissinger, MD
Guest: Guy Young, MD
Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, about 30% of patients treated with factor VIII will develop inhibitors—neutralizing alloantibodies to factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.
However, there is now another option for both patients with and without inhibitors: bispecific antibody non–factor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.
In this educational activity, an expert faculty will review and provide their interprofessional perspectives on currently approved prophylaxis therapy in hemophilia A, including the benefits of prophylaxis and adherence, real-world experience, and patient quality of life factors.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Pediatric and adolescent oncofertility patients are cared for differently than adult patients. That’s why Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital, is here to give us an overview of the available procedures for pediatric patients and the key considerations that go along with them.
Host: Jennifer Caudle, DO
Guest: Maryam Lustberg, MD, MPH
Developing a coordinated survivorship care plan between oncologists and primary care physicians is a top priority for cancer patients. To better understand what goes into this, Dr. Jennifer Caudle is joined by Dr. Maryam Lustberg, Director of The Breast Cancer Center at the Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center, to discuss the role of the primary care physician in survivorship care for breast cancer patients.
Guest: Pavani Chalasani MD, MPH
Has our understanding of HER2 status changed? Dr. Pavanai Chalsani from the University of Arizona Cancer Center dives into the reclassification of HER2 status and shares emerging clinical trial data.
Host: Mark Socinski, MD
Guest: Vivek Subbiah, MD
RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option. Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.
Host: Mark Socinski, MD
Guest: Sandip Patel, MD
Medical innovation in the treatment of lung cancer is at an all-time high. However, the gap between recent developments and their adoption into clinical practice continues to expand for community oncologists as the plethora of scientific and clinical data for the treatment of NSCLC rapidly emerges. Dr. Mark Socinski and Dr. Sandip Patel go through the selection and management of immune checkpoint inhibitors for patients with advanced NSCLC who do not have an actionable mutation.
Host: Hyunseok “Hyu” Kang, MD, MPH
Guest: Jochen Lorch, MD
Although multi-kinase inhibitors (MKIs) have been the standard of care for the treatment of thyroid cancer, they produce excessive “off-target” clinical adverse effects and toxicity that limit their use in some patients, leading to drug discontinuation or dose reduction. The introduction of RET inhibitors into the thyroid cancer treatment landscape offers novel, efficacious therapies for patients who previously had limited treatment options.
This online, on-demand educational activity will review RET alterations in thyroid cancer, molecular diagnostic testing, and recent and emerging clinical data on novel therapies targeting RET-altered or RET-driven thyroid cancer. A Virtual Case Clinic Video Exercise will highlight and demonstrate the translation of these RET-targeted therapies into real-world clinical practice for the treatment of patients with thyroid cancer.
Host: Mark Socinski, MD
Guest: Benjamin Levy, MD
With the availability of more immunotherapies for the management of first-line metastatic NSCLC, PD-L1 status takes on greater importance in determining which approach is best for each patient. Follow along as Dr. Mark Socinski and Dr. Benjamin Levy discuss the factors they use when considering either an immuno-monotherapy or immunotherapy plus chemotherapy approach, and how they monitor for and manage immunotherapy-related adverse events.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
The therapeutic landscape for the first-line treatment of non-driver metastatic NSCLC has become complex and, in some cases, controversial. Based on PD-L1 status, do you know which patients should receive immune checkpoint inhibitor (ICI) monotherapy and when ICI should be combined with chemotherapy? Join Drs. Mark Socinski and Edward Garon as they focus on the intricacies associated with making these therapeutic choices, while also looking at future immunotherapeutic opportunities in the neoadjuvant and adjuvant settings.
Host: Joël Guigay, MD, PhD
Guest: Kevin J. Harrington, MD
Formulating individualized treatment plans for patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN) is increasingly essential and increasingly complex. Newer regimens have become the standard of care because of their efficacy in overall survival and reduced toxicities. So how do we deploy them now that they’re in our treatment armamentarium?
Join Drs. Joël Guigay and Kevin Harrington as they explore the role of IO as the standard of care in SCCHN and discuss the potential of taxanes to reduce dependence on fluorouracil-based chemotherapeutic regimens. Tune in to make sure you’re meeting the needs of your patients’ with SCCHN.
Host: Sara A. Hurvitz, MD, FACP
Guest: William J. Gradishar MD, FASCO, FACP
Guest: Nancy U. Lin, MD
HER2 is overexpressed and/or amplified in about 20% of breast cancers and signifies aggressive tumor behavior. New anti-HER2 therapies are improving the outlook for advanced or metastatic disease with targeted therapeutics, but while physicians now have a multitude of therapies to choose from, patient-specific characteristics and sequencing still present a challenge.
Tune in to enhance your knowledge and skills with this lively panel discussion examining 2 different patient cases with metastatic breast cancer (mBC). Explore optimal treatment selection based on patient-specific characteristics and ensure that you’re keeping up with the rapidly evolving landscape of HER2+ mBC. Find out what changes can make in your practice today to improve the lives of your patients.
Note that this program follows a previous case-based simulation activity titled “Improving the Standard of Care in Community-Based HER2-Positive Metastatic Breast Cancer.” This panel discussion analyzes choices made in that simulation and expands on optimal recommendations. If you haven’t participated in the simulation and would like to put yourself to the test, you can find the link to the activity in the related section.
Since the recording of this interview, additional data have been released specific to efficacy in certain patient subgroups. To learn more about …
Guest: David H. Ilson, MD, PhD
Guest: Jaffer Ajani, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to implement appropriate treatment HER2 strategies for patients with gastric cancer.
Host: Ilene Weitz, MD
Guest: Jamile Shammo, MD, FASCP, FACP
In a “how I do it” clinical commentary, Dr. Jamile Shammo and Dr. Ilene Weitz share their real-world experience in the diagnosis and management of PNH in special patient populations. This case-based activity includes clinical scenarios and treatment strategies to improve patient outcomes.
Guest: Adam M. Brufsky, MD, PhD
Guest: Nina Thomas, MD
Interstitial lung disease (ILD) is a heterogeneous group of diseases that produce inflammation and fibrosis of the parenchyma, affecting the alveolar, interstitial, and vascular spaces. Drug-induced (DI) ILD is associated with a range of novel targeted therapies for the treatment of multiple cancer types, including immune checkpoint inhibitors, CDK 4/6 inhibitors, EGFR tyrosine kinase inhibitors, HER2 targeted therapies, and mechanistic target of rapamycin inhibitors.
Although management of low-grade or asymptomatic ILD with corticosteroid treatment and/or treatment interruption may slow or reverse ILD progression, higher-grade/symptomatic ILD requires permanent discontinuation of therapy. Therefore, it is critical that the interprofessional care team is prepared to monitor for and detect anti-cancer therapy–induced ILD. This educational activity will review the latest evidence and strategies for the early detection of medication-induced ILD and pneumonitis and appropriate management strategies to overcome these treatment challenges in patients who receive select anti-cancer therapies. Expert thought leaders will present relevant information about cancer therapy–induced ILD and pneumonitis and how to integrate the latest advances into real-world clinical practice regarding differential diagnosis, hallmark signs/symptoms, recommended management strategies, implications of patient/caregiver education, and the essentials of team-based management to optimize patient outcomes.
Host: Daniel P. Petrylak, MD
Guest: Arlene O. Siefker-Radtke, MD
It's critical that we select and sequence appropriate therapeutics to provide our patients with the best possible outcomes. Dr. Petrylak and Dr. Siefker-Radtke provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma. With so many new treatment options now available and a cure becoming a real possibility, we invite you to tune in to find out if your treatment strategies are on target.
Host: Mark Socinski, MD
Guest: Justin Gainor, MD
With an expanding arena of available selective RET inhibitors and more data being released on emerging therapies, the landscape for patients with RET-positive metastatic NSCLC is evolving rapidly. Join Drs. Mark Socinski and Justin Gainor as they review the importance of molecular testing in every patient, as well as when to initiate the use of selective RET-inhibitors across multiple lines of therapy. Did we mention you should be testing every patient? Tune in to make sure you’re identifying everyone who can benefit from these newer therapies.
Guest: Rami Komrokji, MD
Guest: Natasha Johnson, MSN, APRN, AOCNP
Myelodysplastic syndromes (MDS) can require lifelong treatment.1 Learn how hematologist-oncologist Dr. Rami Komrokji and nurse practitioner Ms. Natasha Johnson approach their MDS protocol–from characterization, to diagnosis, to treatment. Together, they explain their process for scoring, transplants, and choosing a treatment regimen. They also share their experiences with INQOVI® (decitabine and cedazuridine), the only oral hypomethylating agent in the treatment of MDS, including chronic myelomonocytic leukemia.2
References: 1. Platzbecker U. Treatment of MDS. Blood. 2019;133(10):1096-1107. 2. INQOVI [package insert]. Princeton, NJ: Taiho Oncology, Inc.; 2022.
Host: Lauren Ritterhouse, MD ,PhD
Guest: Pasi Antero Jänne, MD, PhD
Guest: Kanwal Raghav, MD
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
Host: Jacob Sands, MD
Guest: Tejas Patil, MD
What kind of role does next-generation sequencing play in HER2-mutated non-small cell lung cancer? Dr. Jacob Sands is joined by Dr. Tejas Patil from the University of Colorado Medicine to explore the clinical utility of NGS and highlight opportunities to expand molecular testing into clinical practice.
Host: Mark Socinski, MD
Guest: Edward B. Garon, MD, MS
In the treatment of EGFR-mutated advanced non-small cell lung cancer (NSCLC), when is an EGFR TKI not enough? Answer: When you don’t have all of the information. Digging deeper into the specific EGFR mutations has led to advances in the dual blockade of VEGF and EGFR in the frontline setting. Join Drs. Mark Socinski and Edward Garon as they discuss the evolving role of EGFR and VEGF blockade based on clinical trial data. Find out how you can have an immediate impact on your patients by making targeted treatment decisions based on specific oncogenic driver mutations in NSCLC. Be sure to keep up with our experts because making the right choice is more critical than ever.
Host: Misako Nagasaka, MD, PhD
One area of recent progress in the treatment of non–small cell lung cancer (NSCLC) is the development of HER2 targeted therapies for the rare, emerging genetic variant, ERBB2 (HER2) mutations. In fact, the NCCN lists ERBB2 (HER2) mutations as an emerging biomarker to identify novel therapies for patients with metastatic NSCLC. The HER2-directed antibody-drug conjugates (ADC) ado-trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki are now listed as available targeted agents with activity against HER2 mutations. ADCs with other targets such as Trop-2 and HER3 are now also under investigation and showing promise in NSCLC. ADCs have the potential to increase treatment choices for patients with mNSCLC.
For practicing clinicians, this evolution of HER2-directed therapy and ADCs will add to the complexity of NSCLC treatment. This activity will review the emerging role and potential application of ADCs in mNSCLC, including HER2 as a target in NSCLC, biomarker testing, HER2-, HER3-, and TROP2-targeted ADCs, available clinical data on safety and efficacy, evidence-based guideline recommendations, and how newer targeted agents may fit into the treatment paradigm for patients with mNSCLC.
Host: Mark Socinski, MD
Guest: John V. Heymach, MD, PhD
FLAURA and RELAY have changed the landscape of treatment in EGFR-mutant advanced non-small cell lung cancer (NSCLC). But how do know which patients will benefit from these important advances in our knowledge of treating these cancers in the first and subsequent lines of therapy? Join Drs. Mark Socinski and John Heymach as they examine a patient case and discuss the “art” of treatment selection and sequencing of therapy. They also dive into recent advances in the dual blockade of antiangiogenics and TKIs in the frontline setting. Tune in to keep up!
Host: Nabil F. Saba, MD
Couldn’t attend the 2021 European Society of Medical Oncology (ESMO) Conference? No worries—ReachMD host Dr. Nabil Saba is here to share the latest updates in head and neck cancer from the 2021 ESMO Conference.
Host: Jacob Sands, MD
Guest: Joseph Tuscano, MD
While lymphoma can sometimes be difficult to treat, emerging therapies and clinical developments are on the horizon. But could they help improve patient outcomes? Dr. Jacob Sands is joined by Dr. Joseph Tuscano, Physician and Professor of Hematology and Oncology at UC Davis Comprehensive Cancer Center to talk about updates in Lymphoma treatment.
Host: Jeffrey S. Weber, MD, PhD
Approximately half of metastatic cutaneous melanomas carry mutations in BRAF, leading to more aggressive disease. For patients with BRAF V600–activating mutations, treatment options now include the use of combination targeted therapy with BRAF and MEK inhibitors, and combination targeted therapy and immunotherapy. However, even with guideline recommendations, the optimal treatment selection and sequencing is unclear, and additional combination strategies continue to be studied in clinical trials.
In this activity, expert faculty will review and evaluate combination strategies for the treatment of BRAF V600–activating mutation–positive metastatic melanoma, including considerations for treatment selection, sequencing, and management of associated toxicities.
Host: Jennifer Caudle, DO
Guest: Lindsey Roeker, MD
From causes to counseling strategies, Dr. Lindsey Roeker joins Dr. Jennifer Caudle to dive into chronic lymphocytic leukemia fatigue and how we can help our patients who are experiencing this kind of fatigue.
Host: Scott Kopetz, MD, PhD
Guest: Rona Yaeger, MD
Advances in the diagnosis and treatment of mCRC enable personalized care based on the molecular profile of the tumor to achieve improved outcomes. About 5% to 15% of mCRC patients have a mutation in the proto-oncogene BRAF. BRAF is part of an essential cell signaling pathway, mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK). The BRAF V600E mutation induces constitutive activation of BRAF, leading to increased cell growth and proliferation downstream. Patients with the V600E mutation have a 2-fold increased risk for mortality compared to patients with wild-type BRAF, suggesting this gene mutation may act not only as a prognostic biomarker but also as a predictive biomarker. Understanding the current research regarding the consequences of the V600E mutation and testing for it can help guide treatment decision-making in patients with BRAF V600E–mutated mCRC.
This web-based, on-demand activity will feature an expert panel discussion on the latest trends and emerging research in the treatment of BRAF-mutated mCRC. Expert faculty will review and provide their interprofessional perspectives on testing patients for BRAF mutations, recent and emerging data for combination therapies, appropriate treatment selection, and side effect management.
Host: Johann de Bono, MD, PhD
Guest: Alicia K. Morgans, MD, MPH
Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.
This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.
The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Have you considered POMALYST® (pomalidomide) containing regimens for your appropriate patients with relapsed/refractory multiple myeloma who have received lenalidomide and a proteasome inhibitor? Tune in to hear key findings from clinical trials, including safety and efficacy data, and other important information regarding these treatment regimens.
Please see full Prescribing Information for POMALYST, including Boxed WARNINGS, and full Prescribing Information for EMPLICITI.
POMALYST and EMPLICITI Indications
POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
EMPLICITI® (elotuzumab) is indicated in combination with POMALYST and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
POMALYST + dexamethasone + daratumumab Indication
POMALYST + dexamethasone + daratumumab is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Information about POMALYST + dexamethasone + …
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Immune checkpoint inhibitor/tyrosine kinase inhibitor combination therapy has forged to the front-line for the management of metastatic RCC and recurrent RCC, but how do clinicians select the ideal treatment regimen for their patients? How does patient risk status influence the decision-making process? This virtual tumor board features a multidisciplinary expert panel presenting a favorable-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize outcomes in this patient population. Faculty additionally cover the importance of incorporating the patient perspective into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Host: Jacob Sands, MD
Guest: Shirish Gadgeel, MD
Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.
Host: Jennifer Caudle, DO
Guest: Keith McCrae, MD
In order to reflect the evolving management of immune thrombocytopenia (ITP), the American Society of Hematology updated their clinical practice guidelines. Here to share some of the key recommendations for the management of adult and pediatric ITP is Dr. Keith McCrae, a board-certified hematologist and an author of the 2019 ASH Guidelines.
© 2021 Amgen Inc. All rights reserved. USA-531-80829 08/21
Host: Jacob Sands, MD
Guest: Benjamin Kann, MD
Artificial intelligence-based models have become a growing area of interest in clinical oncology. What do we need to know about them? Dr. Benjamin Kann, a physician at Dana Farber Cancer Institute, and Assistant Professor of radiation oncology at Harvard Medical School, meets with Dr. Jacob Sands to discuss the use of AI in oncology.
Host: Jennifer Caudle, DO
Guest: Mikkael A. Sekeres, MD, MS
Guest: Sara M. Tinsley, PhD, ARNP, AOCNP
Please note: This activity is no longer available for continuing education credit.
There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and developing strategies based on the evolving implications of this research will allow for greater understanding of their potential impact on management and health outcomes of patients with MDS, CMML, and AML.
Host: Arjun V. Balar, MD
Guest: Daniel P. Petrylak, MD
Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when determining an appropriate treatment plan. Until recently, platinum-based chemotherapy was the only viable systemic therapy option for patients with locally advanced or metastatic urothelial cancer (mUC); however, the majority of these patients eventually relapse and need subsequent lines of therapy. Patients are then left with limited treatment options and often poor outcomes, contributing to a largely unmet need that prompted investigation into new and promising therapeutic options.
This chapterized activity is designed to update clinicians who treat locally advanced or metastatic urothelial cancer on new clinical trials and the treatment guidelines that align with the identified unmet need of subsequent treatment options for this patient population. Drs. Arjun Balar and Daniel Petrylak focus on enhancing the knowledge and skills of clinicians through case-based content to demonstrate individualized patient treatment plans and enable participants to further incorporate changes into their clinical practice. Join us to find out why the future is bright for our patients with mUC.
Host: Jay Raman, MD, FACS
Guest: Oguz Akin, MD
Guest: Robert J. Motzer, MD
Guest: Elizabeth Plimack, MD, MS
Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.
After viewing the activity, visit the Related tab for supplemental resources.
Guest: Maria E. Arcila, MD
Guest: Alexander Drilon, MD
Capitalizing on the advances in identification of oncogenic driver mutations, genetic testing, and therapeutic approaches that target actionable mutations, targeted therapy is the current standard of care in NSCLC. The use of molecular testing and targeted therapies has yielded remarkable and practice-changing improvements for patients harboring these actionable mutations.
The current availability of multiple targeted agents, such as second- and third-generation ALK and ROS1 tyrosine kinase inhibitors, some of which are approved for use both in first-line and subsequent lines of therapy, coupled with the presence of concomitant actionable mutations, can make selection of the appropriate targeted treatment for eligible patients complicated.
This web-based, on-demand activity will feature an expert panel that will provide their interprofessional perspectives on the latest trends and emerging research regarding biomarker testing and evidence-based biomarker-guided targeted therapy for patients with NSCLC with ROS1 and ALK rearrangements.
Host: Jacob Sands, MD
Guest: Brad McGregor, MD
Non-clear cell renal cell carcinoma is one of the rare diseases with limited treatment data, creating many challenges for oncologists. But could recent updates radically change the landscape? To find out, Dr. Jacob Sands speaks with Dr. Brad McGregor, the Clinical Director for the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, to discuss developments in the management of non-clear cell renal cell carcinoma.
Host: Jacob Sands, MD
Guest: Derek Raghavan, MD, PhD, FACP, FRACP
CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Host: Ezra Cohen, MD
Guest: Barbara Burtness, MD
Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
Host: Matt Birnholz, MD
Guest: Jacob Sands, MD
ReachMD hosts Drs. Matt Birnholz and Jacob Sands come together to discuss the rationales, limitations, and pathways forward in the treatment of relapsing small cell lung cancer as well as platinum rechallenge therapy.
Guest: Rami Manochakian, MD
Dr. Rami Manochakian, a thoracic medical oncologist at the Mayo Clinic, dives into three clinical trials on developments in lung cancer treatment that were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Nina Delaney Wagner-Johnston, MD
Guest: Seema A. Bhat, MD
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy associated with different cytogenetic, immunophenotypic, and morphological profiles. This diversity has resulted in varying clinical courses and responses to therapy and underscores the importance of individualizing therapy. The availability of targeted therapies has dramatically transformed the CLL therapeutic landscape, providing options for personalized treatments within both the newly diagnosed and relapsed/refractory (R/R) settings.
In this educational activity, faculty members review current efficacy and safety data for targeted therapies approved for patients with treatment-naïve or R/R CLL, as well as emerging strategies for treatment. They evaluate clinical trial data, along with patient- and disease-related factors, that allow for the individualization of therapy selection and sequencing of therapy in first and second lines of therapy and beyond.
Host: Michael Greenberg, MD
Guest: Sam Polesie, PhD
Can technology play a role in assessing melanoma? Dr. Michael Greenberg discusses the use of artificial intelligence in dermatology with Dr. Sam Polesie, a specialist physician in the Department of Dermatology and Venereology at the Sahlgrenska University Hospital in Gothenburg, Sweden.
Guest: Javier Cortes, MD, PhD
Guest: Sara A. Hurvitz, MD, FACP
While HER2+ breast cancers are traditionally associated with a poor prognosis, the development of HER2-directed treatment strategies has led to substantial and durable survival improvements, even in patients with metastatic disease. Nonetheless, a percentage of these patients will not respond to certain therapies, and many may become resistant within a year of treatment.
In this chapterized activity, Dr. Javier Cortes and Dr. Sara Hurvitz discuss optimal therapy selection based on individual patient characteristics as well as strategies to manage potential adverse events associated with current treatment options for HER2+ metastatic breast cancer.
Host: Samilia Obeng-Gyasi, MD, MPH
How do surgical delays play a role in breast cancer outcomes? Dr. Samilia Obeng-Gyasi, an Assistant Professor of Surgery at Ohio State University, shares insight from her presentation at the 2021 American Society of Clinical Oncology Annual Meeting.
Host: Joel Wedd MD, MPH
Not only is hepatocellular carcinoma (HCC) the most common primary liver cancer in adults, but it’s also the fastest-growing cause of cancer-related deaths in the US. That’s why Dr. Joel Wedd, Associate Professor of Medicine at the Virginia Commonwealth University and Medical Director of Liver Transplant at the Hume-Lee Transplant Center, is here to discuss the pathogenesis of hepatocellular carcinoma, risk factors, the importance of early-stage detection, and more.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lincoln Nadauld, MD, PhD
Current cancer screening methods like mammograms, colonoscopies, and CT scans are all effective in detecting cancers, but they don’t always detect cancers as early as we’d like them to, resulting in missed and delayed diagnoses. Could new technology like multicancer early detection (MCED) be the answer to addressing current unmet needs in cancer screening? Find out with Dr. Charles Turck and Dr. Lincoln Nadauld, an oncologist and the Vice President and Chief of Precision Health and Academics at Intermountain Healthcare.
Host: Paul Paik, MD
Guest: Joshua K. Sabari, MD
For the 3% to 4% of patients with non-small cell lung cancer (NSCLC) who harbor a MET exon 14 skipping mutation, the prognosis is grave. MET gene dysregulation may also play a role in the emergence of resistance to EGFR TKI therapy in patients with EGFR-mutated NSCLC, further complicating treatment. Join our case discussion as Dr. Paul Paik and Dr. Josh Sabari highlight the importance of identifying MET gene aberrations in patients with NSCLC.
Guest: D. Ross Camidge, MD, PhD
The discovery of predictive biomarkers, such as sensitizing epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, ROS1 rearrangements, and BRAF V600E mutations has led to an improvement in overall survival and progression-free survival in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatment. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) note, “For patients with recurrent and metastatic disease, the NCCN Guidelines recommend that histologic subtype should be determined before therapy so that the best treatment can be selected. In addition, biomarker testing for genetic alterations (ie, oncogenic driver events) is recommended in patients with NSCLC, because targeted therapy has been shown to decrease tumor burden, decrease symptoms, and dramatically improve the quality of life for patients with specific genetic alterations. The number of available targeted agents is increasing.” (Ettinger et al, 2020.)
Approximately 5% of patients with NSCLC have ALK gene rearrangements. One of the most noteworthy areas of progress is the development of effective ALK-targeting therapies to treat NSCLC, including crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. Because of the fast pace of developments in this area, it may be difficult for clinicians to remain up-to-date on …
Host: Loretta J. Nastoupil, MD
Guest: John P. Leonard, MD
Recent clinical trial evidence supports the use of available and emerging options in relapsing/refractory follicular lymphoma. In this case-based activity, Dr. Loretta Nastoupil and Dr. John Leonard discuss the importance of testing for EZH2 mutations in follicular lymphoma, choosing the appropriate treatment option for each patient, and how to minimize risk to improve patient outcomes.
Host: Jacob Sands, MD
Guest: Millie Das, MD
What are some of the latest advancements in small cell lung cancer? Dr. Jacob Sands discusses small-cell lung cancer treatment developments with Dr. Millie Das, a Clinical Associate Professor of Medical Oncology at Stanford University and Chief of Oncology at the Veteran’s Affairs Palo Alto Healthcare System.
Host: Loretta J. Nastoupil, MD
Guest: Gilles Salles, MD
Follicular lymphoma (FL) is an incurable neoplasm that is frequently associated with relapse and refractory (R/R) disease. In this activity, Drs. Loretta Nastoupil and Gilles Salles will review the role of EZH2 modulation in FL and explain the role that EZH2 inhibition can play in R/R disease. They will also discuss the many available oral therapeutic options and emerging therapies on the horizon, recent data from those clinical trials, and where these therapies will fit into clinical practice.
Guest: Andy Arwari, MD
With more patients opting for home-based care over long-term, acute, and office-based care, it’s important that we align with our patients on what’s most important to them and how they want to be cared for, especially those who are nearing the end of life.
That’s why VITAS Medical Director, Dr. Andy Arwari, is here to share the purpose of goals-of-care conversations and how an app can aid in determining if an advanced illness patient is eligible for hospice.
Guest: Chandrajit P. Raut, MD, MSc
Dr. Chandrajit P. Raut, Chief of the Division of Oncology at Brigham and Women’s Hospital, gives us a sneak preview of his presentation on the surgical management of breast angiosarcoma at the upcoming 2021 American Society of Clinical Oncology Annual Meeting.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christine Bestvina, MD
Dr. Charles Turck sits down with Dr. Christine Bestvina, Assistant Professor of Medicine in the Section of Hematology and Oncology at University of Chicago Medicine, to discuss best practices and adverse events when it comes to treating non-small cell lung cancer.
Host: Jacob Sands, MD
Guest: Mark Awad, MD, PhD
What do we need to know about the role of biomarkers in non-small cell lung cancer? Dr. Mark Awad from the Dana-Farber Cancer Institute explains.
Host: Paul Paik, MD
Guest: Viola Zhu, MD
Dysregulation of MET signaling has been widely described in oncogenic processes. While all 3 types of MET dysregulation (amplification, overexpression, and gene mutations) have been documented in non-small cell lung cancer (NSCLC), MET exon 14 skipping alterations are a primary oncogenic driver in approximately 3% to 4% of these patients, often with a poor outcome. Join us as Dr. Paul Paik and Dr. Viola Zhu discuss the importance of testing patients for MET gene aberrations and their relevance in the management of NSCLC, especially as related to recently approved and emerging therapies for patients harboring a MET gene aberration.
Host: Loretta J. Nastoupil, MD
Guest: Matthew J. Matasar, MD
The epigenetic modulator EZH2 is known to play a crucial role in mediating the lymphomagenesis of follicular lymphoma (FL), and the inhibition of EZH2 in the relapsing/refractory disease setting has shown efficacy. In this activity, Drs. Matasar and Nastoupil discuss the role of EZH2 in the pathobiology of FL, emphasize the need to test for mutations in EZH2 in FL, and explore the potential of targeting EZH2 in different settings of FL treatment.
Host: Oudai Hassan, MD
Here to examine the updated ASCO and CAP joint guidelines and their recommendations in the ongoing mission to improve the accuracy of HER2 testing is Dr. Oudai Hassan.
Host: Julien Taieb, MD, PhD
Guest: Scott Kopetz, MD, PhD
BRAF mCRC is a very aggressive subset of colon cancer and, until recently, treatment options have been very limited. With a new standard of care on the rise, a critical challenge remains: How will emerging regimens be utilized in daily clinical practice?
Join us as 2 experts, Dr. Scott Kopetz and Dr. Julien Taieb, examine strategies to enhance the personalized management of patients with BRAF V600E-mutated mCRC.
Host: Daniel Catenacci, MD
Guest: Yelena Janjigian, MD
Do you face clinical challenges when managing patients with advanced HER2-positive gastric cancer? You’re not alone. Advanced gastroesophageal cancers remain among the most difficult cancers for clinicians to manage. One of the many challenges to optimizing patient outcomes is a relative lack of familiarity with practice standards regarding HER2-positive disease. While HER2 is an oncogenic driver in gastroesophageal cancers, it does not appear to act as a predictive biomarker in quite the same way as it does in breast cancer. However, there are ways to fully optimize anti-HER2 therapy in gastroesophageal cancers. Join us as Dr. Daniel Catenacci and Dr. Yelena Janjigian demystify HER2-positive gastroesophageal cancers and provide insights for the integration of personalized therapeutic approaches for these patients.
Guest: James Lewis II, PharmD, FIDSA
Guest: George Thompson III, MD, FIDSA
Have you ever wondered what went wrong in the management of invasive fungal infections? Through a storytelling approach Dr. James Lewis & Dr. George Thompson discuss a clinical story and identify where medical misses may have occurred. Supportive evidence will be provided on how care should have been provided and strategies for clinicians to apply in their practice.
Host: Richard T. Penson, MD, MRCP
Guest: Ana Oaknin, MD
Therapeutic choices for many women with advanced endometrial cancer are being driven by our understanding of the mismatch repair (deficient/proficient) and microsatellite (instable/stable) status of their tumors. Join us as Dr. Richard Penson and Dr. Ana Oaknin discuss the global perspective surrounding the recent emergence of immunotherapy agents in the management of recurrent or metastatic endometrial cancer. Find out how to manage the toxicities of these newer therapies and discover just how critical a role molecular testing plays in selecting which patients receive a particular therapeutic strategy.
Host: Richard T. Penson, MD, MRCP
Guest: Nicoletta Colombo, MD
Guest: Christine Ghione
Therapeutic options are changing for many patients with advanced endometrial cancer. Join us as Dr. Richard Penson and Dr. Nicoletta Colombo discuss new immunotherapeutic approaches and the importance of a patient’s tumor genomic profile when determining which interventional strategy, they receive. Also hear from Ms. Christine Ghione, a patient advocate, who provides a firsthand perspective of shared decision-making and how the process may be improved.
Since the production of this activity, the FDA has approved the use of dostarlimab for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA-approved test. Visit the FDA statement dated 22 April 2021 to learn more.
Guest: D. Ross Camidge, MD, PhD
After starting on a RET inhibitor, what do you do? Dr. Ross Camidge, the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, breaks down the progression of RET inhibitors in patients with non-small cell lung cancer and what tests should be utilized throughout the process.
Host: Robert Mocharnuk, MD
Guest: Johann de Bono, MD, PhD
Guest: Neeraj Agarwal, MD
During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.
PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.
In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a …
Host: Pallav Mehta, MD
What is the role of autoantibodies in breast cancer detection? Dr. Pallav Mehta, the Director of Integrative Oncology and Practice Development at the MD Anderson Cancer Center at Cooper University Health Care, shares the latest research on autoantibodies as potential biomarkers in the early detection of breast cancer?
Host: Paul Paik, MD
Guest: Jyoti D. Patel, MD, FASCO
Lung cancer remains the most common cancer in the United States and Europe and second most common in Japan. Of patients with non-small cell lung cancer (NSCLC), approximately 3% to 4% have tumors that harbor MET gene aberrations including MET exon 14 skipping mutations. These patients have an even worse prognosis than others with NSCLC, and early diagnosis and targeted therapies are essential. Join us as Dr. Paul Paik and Dr. Jyoti Patel discuss the value that liquid biopsy brings to patients with NSCLC, specifically those with MET exon 14 skipping mutations.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Rajeev Attam, MD
Pancreatic cysts may be detected in up to 50 percent of patients undergoing intraabdominal MR imaging. But not all of them are malignant, so how can we determine which patients need further testing, monitoring, and perhaps even surgery? Joining Dr. Peter Buch to answer that and other questions is gastroenterologist Dr. Rajeev Attam.
Guest: D. Ross Camidge, MD, PhD
What are some of the clinical considerations for RET-rearranged non-small cell lung cancer? Dr. Ross Camidge, Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado, briefly discusses the guidelines and benefits of therapy recommended for non-small cell lung cancer by the National Comprehensive Cancer Network.
Host: Jacob Sands, MD
Guest: Andrea B. McKee, MD
How can a lung screening program enhance the quality of care for patients with lung cancer? Dr. Andrea McKee, Chair Emeritus in Radiation Oncology and Director of the Lung Screening Program at Lahey Hospital and Medical Center, shares how she and her colleagues designed this program at Lahey Hospital and Medical Center.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Adam Olsen, MS, PA-C
Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.
Guest: Manisha Bahl, MD
What’s recent research saying about the use of tomosynthesis versus conventional 2D digital mammography to screen for breast cancer? Find out with Dr. Manisha Bahl, a breast imaging radiologist and Assistant Professor of Radiology at Harvard Medical Center.
Host: Hector O. Chapa, MD, FACOG
Guest: Cameron Ayala
Hundreds of millions of people worldwide suffer from lymphedema and lymphatic diseases. Joining us to provide a personal perspective on this condition is Cameron Ayala, a former reality TV persona, compression specialist, and lymphedema patient who will be sharing his experience with Dr. Hector Chapa.
Host: Jacob Sands, MD
Guest: Aaron S. Mansfield, MD
There are different treatment options available for early-stage mesothelioma, and there seem to be differences in standard practice from one center to the next. Joining Dr. Jacob Sands to share how he approaches the treatment of early-stage mesothelioma using the latest options is Dr. Aaron Mansfield, an Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.
Host: Shannon L. Meeks, MD
Guest: Jonathan C. Roberts, MD
Dr. Shannon Meeks and Dr. Jonathan Roberts give an overview of the treatments used for the management of hemophilia A and discuss the safety and efficacy of these treatments. Using a patient case, they illustrate the pharmacovigilance process and explain how to implement this important reporting structure into everyday practice.
Guest: Monica L. Baskin, PhD
Guest: Josep M. Llovet, MD, PhD
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. Patients with advanced disease at diagnosis typically are not candidates for potentially curative treatment options, such as resection, liver transplantation, or ablation. Additionally, liver cirrhosis and hepatic dysfunction often complicate treatment. Advances in the understanding of the molecular pathogenesis of HCC have broadened the potential for effective molecular targeted therapies, and advances in immune checkpoint inhibitor therapy are now transforming the way clinicians treat HCC.
Of particular concern, HCC incidence and mortality rates have risen among American Indian/Alaska Native, Hispanic, and black populations in the United States in recent years. Incidence of HCC is also expected to increase in older populations due to hepatitis C, a risk factor for development of HCC, among other comorbid conditions such as cirrhosis, obesity, diabetes, and non-alcoholic steatohepatitis, which are also on the rise. Screening and surveillance of these conditions that contribute to the development of HCC occur less often in many Hispanic and black populations, which can delay diagnosis and leave them ineligible for curative resection or transplantation due to advanced disease, leading to worse prognosis.
In this activity, the expert faculty will review health disparities, inequities, and …
Host: Shannon L. Meeks, MD
Guest: Cindy Leissinger, MD
Pharmacovigilance begins after clinical trials end and new therapies enter everyday practice. Due to the rarity of hemophilia, participation in clinical trials has necessarily been small, and so monitoring the safety of new hemophilia treatments is especially important. Continued surveillance of adverse drug reactions (ADRs) after approval is a responsibility that falls on all members of the care team.
Dr. Shannon Meeks and Dr. Cindy Leissinger discuss the importance of safety surveillance and monitoring for novel hemophilia A therapeutics. To give a better understanding of pharmacovigilance, this activity includes animation that breaks down the process and illustrates where your ADR reports go and what happens next.
Host: Federico Cappuzzo
Guest: Professor Solange Peters
Guest: Professor Yi-Long Wu
Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.
Host: Floor J. Backes, MD
Guest: Robert L. Coleman, MD, FACOG, FACS
Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.
Host: Charles E. Geyer, Jr., MD, FACP
Guest: Hope S. Rugo, MD
Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.
In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.
Host: Peter Schmid, FRCP, MD, PhD
Guest: Javier Cortes, MD, PhD
Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the role of immunotherapies in the treatment of metastatic TNBC and how to determine if your patient is eligible for combination immunotherapies.
Guest: Lajos Pusztai, MD
What are the current rationales for the use of adjuvant therapies in the management of early-stage breast cancer patients? Here to share some insights is Dr. Lajos Pusztai, Director of Breast Cancer Translational Research at the Yale Cancer Center.
Host: Neilanjan Nandi, MD
Guest: Folasade P. May, MD, PhD, MPhil
Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalities in access to care and screening for patients with colorectal cancer.
Host: Jacob Sands, MD
Guest: Aaron S. Mansfield, MD
Mesothelioma is a cancer with limited treatment options, so how can we manage it in the first and second-line settings and beyond? Here with Dr. Jacob Sands to walk us through the various treatment approaches to mesothelioma is Dr. Aaron Mansfield, Associate Professor of Oncology and Co-Director of Precision Cancer Therapeutics at Mayo Clinic in Rochester.
Host: Hector O. Chapa, MD, FACOG
Guest: Andrew Little, DO
When vascular access is compromised, intraosseous access, or IO access, can help prevent fatal consequences. What do we need to know about implementing and managing this type of device? Dr. Hector Chapa is joined by Dr. Andy Little, the Associate Program Director for AdventHealth Orlando Emergency Medicine Residency, to share some insight on IO vascular access.
Host: Jacob Sands, MD
Guest: Pasi Antero Jänne, MD, PhD
Once we’ve confirmed a patient has EGFR-mutated lung cancer, how can we treat them? Joining Dr. Jacob Sands to discuss the current and future treatments for this mutation is Dr. Pasi Janne, a translational thoracic medical oncologist at the Dana-Farber Cancer Institute.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nicole Lamanna, MD
The anti-apoptotic protein B-cell lymphoma 2 (BCL2) is a key regulator of the intrinsic apoptotic pathway and is often overexpressed in chronic lymphocytic leukemia (CLL) cells. That’s why BCL2 represents an important therapeutic target for CLL, and joining Dr. Charles Turck to look at Venetoclax, a treatment option that targets this protein is Dr. Nicole Lamanna, an Associate Clinical Professor of Medicine at Columbia University Medical Center in New York.
Host: Jacob Sands, MD
Guest: Benjamin Levy, MD
What is genomic testing, and how has this advancement become such an important part of lung cancer treatment? Dr. Jacob Sands is joined Dr. Ben Levy, an associate professor of oncology at the Johns Hopkins University School of Medicine to discuss targeted therapies and testing strategies in patients with lung cancer.
Host: Jacob Sands, MD
Guest: Lawrence Nathan Shulman, MD
How do challenges in our healthcare system and disparities in access to care impact cancer patients within our communities? Dr. Jacob Sands and Dr. Lawrence Shulman continue their important conversation on oncology around the world.
Guest: Joseph Mikhael, MD
A 15-minute synopsis of the top hematology research in multiple myeloma presented at the 2020 ASH Annual Meeting. Learn about potential practice-changing data placed in a real-world context by a myeloma expert. This activity is an opportunity to stay up to date on the rapidly evolving myeloma landscape and to enhance your management and care strategies for patients with multiple myeloma.
Host: John J. Russell, MD
Guest: Steven W. Pipe, MD
Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.
Click here to access patient information on hemophilia from the CDC.
Host: Jennifer Caudle, DO
Guest: Coy Heldermon, MD, PhD
Guest: Heather Lau, MD, MS
Several questions are often brought to light when it comes to detecting and diagnosing Gaucher disease, such as how does it present, what genetic factors to consider, and how to go about making an accurate diagnosis. Here to answer those and other questions are practicing hematologist oncologist Dr. Coy Heldermon and neurogeneticist Dr. Heather Lau.
For more information on the diagnostic and therapeutic landscape for Gaucher disease, including access to Sanofi Genzyme Rare Disease Registries, visit Gauchercare.com/hcp, a Sanofi Genzyme website.
MAT-US-2024074 2/2021
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Harry Paul Erba, MD, PhD
Guest: Uma Borate, MD, MS
With the development of technologies paired with an enhanced understandings of the AML genomic landscape, it’s become possible to develop targeted AML therapies. Joining Dr. Charles Turck to explore Venetoclax and its role in current AML treatment paradigms are Drs. Uma Borate and Harry Erba.
Host: John J. Russell, MD
Guest: Adam Hill, MD
Dr. John Russell is joined by pediatric oncologist Dr. Adam Hill, author of “Long Walk Out of the Woods,” to discuss depression among healthcare professionals and address trauma faced in the medical field.
Host: John J. Russell, MD
Guest: Rose George
Dr. John Russell is joined by Rose George, the author of the book “Nine Pints," to take an in-depth look into everything we know about blood.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Joseph C. Anderson, MD
Colon cancer rates for patients younger than 50 have increased at an alarming rate. How can we help screen our younger individuals for colon cancer? Tune in to hear Dr. Peter Buch speak with Dr. Joseph Anderson, Associate Professor of Medicine at Dartmouth, to discuss the transitions occurring in colon cancer screening.
Host: Jacob Sands, MD
Cancer care has evolved since the initial outbreak of the COVID-19 pandemic. What do we need to know about caring for our cancer patients during this winter season? Dr. Jacob Sands, Thoracic Medical Oncologist at the Dana-Farber Institute in Boston shares what cancer patients can do to take care of themselves during the winter season.
Guest: Mariana Chavez MacGregor, MD, MSC
The healthcare disparity crisis in the breast cancer field has prevented the benefits of therapeutic advancements from being equally distributed throughout all populations. What can we do to overcome this obstacle? Dr. Mariana Chavez MacGregor, Associate Professor at the University of Texas MD Anderson Cancer Center, talks about the disparities she's encountered in breast cancer care.
Guest: Christopher Lathan, MD, MS, MPH
Healthcare professionals have found that zip code is a better indicator of health for many patients rather than cholesterol or genetics, highlighting a significant disparity in the field of medicine. What can we do to overcome this obstacle? Dr. Christopher Lathan, Associate Medical Director of the Dana Farber Cancer Institute Network, explains how we can better connect with our patients to improve their care.
Host: Jacob Sands, MD
Guest: Taofeek K. Owonikoko, MD, PhD, MSCR
After years without new approvals, advancements in small cell lung cancer are at the forefront of oncology. But what do these therapeutic developments mean for the field? Dr. Taofeek Owonikoko, professor and vice-chair for faculty development in the Department of Hematology and Medical Oncology at Emory University School of Medicine, joins Dr. Jacob Sands to talk about long-awaited developments in small cell lung cancer.
Host: Jacob Sands, MD
Guest: Nabil F. Saba, MD
Since head and neck cancer is still to a large extent a surgical disease, the COVID-19 pandemic had an immediate impact on its management. Here to share how he pivoted his approach and how the pandemic might impact the future of head and neck cancer care is Dr. Nabil Saba, a Professor and Vice Chair for Quality and Safety in the Department of Hematology and Medical Oncology at the Emory University School of Medicine.
Host: Jacob Sands, MD
Guest: Therese T. Bevers, MD
Fear of the COVID-19 pandemic has led to added safety precautions that have prevented patients from receiving much-needed cancer screenings. How will this impact the field of oncology, and what can we do to encourage patients to get their screenings? Dr. Therese Beavers, Medical Director of the Cancer Prevention Center at the University of Texas MD Anderson Cancer Center, joins Dr. Jacob Sands to discuss the fatal consequences of missed cancer screenings.
Guest: Lauren K. Brooks, MD
During this unprecedented time, finding the best approach to providing treatment for patients with thyroid cancer can be a challenge. Endocrinologist Dr. Lauren Brooks of Penn Medicine Lancaster General Health shares some of her approaches to this dilemma and stresses the importance of keeping up on routine practices during the COVID-19 pandemic.
Published September 28, 2020
Guest: Emily F. Conant, MD
When stay-at-home orders were put into place, healthcare institutions were forced to adapt the way they screen, care for, and treat patients. With that in mind, Dr. Emily Conant, Professor of Radiology at the Hospital of the University of Pennsylvania, explains their three-step process to keep breast cancer patients and staff safe during the COVID-19 pandemic.
Published September 23, 2020
Guest: Gregory J Kubicek, MD
When caring for patients who are at greater risk of complications from COVID-19, what extra precautions are needed to help keep them safe and healthy? That’s what staff radiation oncologist Dr. Gregory Kubicek from the MD Anderson Cooper Cancer Center shares with us.
Published June 23, 2020
Host: Jennifer Caudle, DO
Guest: Tracey Evans, MD
Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.
In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1
Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2
Visit TagrissoHCP.com to learn what these data could mean for your patients.
FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …
Host: Jennifer Caudle, DO
Guest: Kathryn J. Ruddy, MD
Guest: Joerg Herrmann, MD
As the number of cancer survivors continues to grow due to treatment advances, so too do the long-term impacts like cardiovascular complications. That’s why the field of cardio-oncology has emerged, and to learn more, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Anthony Dragun, MD
Throughout this global pandemic, radiation oncologists are faced with the challenge of finding ways to continue administering the necessary cancer treatments while limiting their patients’ risk of exposure to COVID-19. Dr. Anthony Dragun from the MD Anderson Cancer Center is here to explain how that can be done and why these new approaches should be embraced even after the COVID-19 pandemic is over.
Published April 27, 2020
Host: Mario R. Nacinovich, Jr., MSc
Guest: Jonathan Riess, MD, MS
Due to the many challenges and complications that are now facing oncologists and their patients requiring lung cancer treatment, lung cancer care is changing in many ways to help minimize a patient’s risk of exposure, as Dr. Jonathan Riess from the UC Davis Medical Center explains.
Published April 24, 2020
Host: Paul Doghramji, MD
Guest: Gary Lyman, MD, MPH
Just two miles away from where the first case of COVID-19 was identified, the Hutchinson Institute for Cancer Outcomes Research acted quickly to help protect patients. Here to walk us through the impacts, barriers faced, and strategies that have been implemented to help address those challenges is the oncology center’s Senior Lead of Health Care Quality and Policy Dr. Gary Lyman.
Published April 10, 2020
Guest: Jason Day
Guest: Dening Day
Biomarker testing is a critical step in any mNSCLC patient’s treatment journey, as PGA champion Jason Day found out when his mother, Dening, was diagnosed with the disease.1-3
In this video, Jason and Dening tell their story about how biomarker testing helped Dening get on a therapy that can target the driver of her disease. Jason and Dening’s story may help your newly diagnosed mNSCLC patients understand the importance of testing their lung cancer, knowing the full molecular results, and treating based on those results.
Share this video and more with your patients by visiting TestLungCancer.com.
References:
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J …
Host: John J. Russell, MD
Guest: Nabil Wasif, MD
Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.
Short for hyperthermic intraperitoneal chemotherapy, HIPEC is a form of treatment for advanced cancers of the gastrointestinal tract, like metastatic appendix, colon, and ovarian cancers. And after a recent Mayo Clinic study investigated the survival rates of patients who received HIPEC, Dr. Nabil Wasif joins us to discuss the study’s results as well as the benefits and drawbacks of HIPEC.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Jennifer Caudle, DO
Guest: Robert Foote, MD
Guest: Anita Mahajan, MD
Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.
When compared to traditional x-ray radiation therapy, proton beam therapy is a more targeted form of therapy that offers a lower dose of radiation to impacted organs and fewer side effects and complications, which explains why its being recommended as a treatment option more and more. But what are some of the other benefits—and challenges—of proton beam therapy? That’s what Drs. Anita Mahajan and Robert Foote are here to discuss.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Chee-Chee Stucky, MD
Image: Mayo Foundation For Medical Education and Research. All Rights Reserved.
About a third of the 55,000 Americans diagnosed with pancreatic cancer each year were considered inoperable due to the tumor growing outside the pancreas. But now, that conventional wisdom is being challenged with the release of data from a recent study, as Dr. Chee-Chee Stucky, a surgical oncologist from Mayo Clinic, explains.
For more information about referring a patient to Mayo Clinic, please visit mayoclinic.org and for continuing medical education opportunities visit ce.mayo.edu.
Host: Jennifer Caudle, DO
Guest: William Levin, MD
To explore the complementary approaches to care that are making an impact in the oncology field, Dr. William Levin joins Dr. Jennifer Caudle to discuss how integrative therapy can help reduce stress and anxiety in cancer patients and their caregivers.
Host: Jenn Simmons, MD
Guest: Susan Domchek, MD
Anytime the topic of genetic testing comes up in the context of breast and ovarian cancers, one question that undoubtedly arises is: who exactly should be tested? That’s the FAQ Dr. Susan Domchek, Director of the McDonald Women’s Cancer Risk Evaluation Center at the Hospital of the University of Pennsylvania, answers.
Host: Eric H. Kraut, MD
Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.
Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Clinicians will be challenged to integrate these new agents into their clinical practices.
AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when …
Host: Leora Horn, MD, MSc
Please note: This activity is no longer available for continuing education credit.
Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with a poor prognosis. The recent addition of immunotherapy to the treatment landscape has changed the standard of care for ES-SCLC. In this interactive activity an expert will guide you through the latest evidence on checkpoint inhibitors for the management of ES-SCLC and offer expert insight into effectively and safely incorporating immunotherapy into your practice to improve patient outcomes.
Host: Chrysalyne D. Schmults, MD, MSCE (Chair)
Guest: Omid Hamid, MD
Guest: Anokhi Jambusaria, MD, MSCE, FAAD
Please note: This activity is no longer available for continuing education credit.
Available treatment options for cutaneous squamous cell carcinoma (cSCC) are expanding and involving more interdisciplinary dialogue. This slides/audio presentation features 3 clinical case scenarios with feedback and commentary by a medical oncologist, surgeon, and dermatologist exploring topics in immunotherapy, Mohs surgery, and complex patient presentations.
Host: Chrysalyne D. Schmults, MD, MSCE (Chair)
Guest: Omid Hamid, MD
Guest: Anokhi Jambusaria, MD, MSCE, FAAD
Please note: This activity is no longer available for continuing education credit.
The recent approval of the first immunotherapeutic agent for cutaneous squamous cell carcinoma (cSCC) is changing the way healthcare providers treat patients with inoperable cSCC. In this roundtable discussion, a cSCC survivor draws upon his experience with the cancer when surgery and chemotherapy failed him, as our multidisciplinary faculty panel focus on how to optimally select patients with cSCC for treatment with immunotherapy.
Host: Jennifer Caudle, DO
Guest: Suhail K. Kanchwala, MD
Improving his patients’ post-surgical experience was Dr. Suhail Kanchwala's goal when he sought to develop a new method for autologous breast reconstruction. The result of his search has brought a new technique to the field, along with an array of benefits for patients, including reduction of post-surgical pain and opioid use.
Host: Brian P. McDonough, MD, FAAFP
Palliative and hospice care both have very important roles in healthcare, but unfortunately, they are often overlooked as resources.
Dr. Brian McDonough is joined by Chief Medical Officer of Samaritan Healthcare & Hospice Dr. Stephen Goldfine, who offers his perspective on the stigma surrounding these two areas of healthcare and recommendations on how to make the conversation easier for you and your patients.
Host: Jennifer Caudle, DO
The month of September is dedicated to raising awareness of sickle cell disease, which affects approximately 70,000 to 100,000 Americans each year. Here to tell us more about this prevalent condition and the various resources available is Dr. Jennifer Caudle.
Host: John J. Russell, MD
Guest: Richard Wender, MD
From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations.
For more information and to review the new guidelines, go to cancer.org
Host: Shira Johnson, MD
Guest: Ronald DeMatteo, MD, FACS
A Gastrointestinal Stromal Tumor (GIST) is a rare sarcoma that begins in the digestive tract or stomach, with an incident rate in the United States of approximately 4,000 to 6,000 cases per year. Since these tumors behave differently from other gastrointestinal cancers, they require a specialized treatment plan.
Host Dr. Shira Johnson chats with Ronald DeMatteo, MD, FACS, Chair of the Department of Surgery and a surgical oncologist at Penn Medicine. They discuss the diagnosis, treatment and current clinical research of GIST. Dr. DeMatteo is a world-renowned surgical expert and researcher for the rare GIST. His research breakthroughs helped develop the new standard of care for GIST.
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.
Released on December 21, 2017
Host: Shira Johnson, MD
Guest: Robert Vonderheide, MD
For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer.
But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well.
Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.
Host: Brian P. McDonough, MD, FAAFP
Cigarette smoking is one of the leading cause of preventable death in North America, an unfortunate statistic that is rapidly replicating across the rest of the world. The World Health Organization (WHO) predicts based on current trends that cigarette smoking will kill a billion people this century.
But what can be done to reverse this trend?
Host Brian McDonough talks with David Sweanor, Adjunct Professor of Law, and Chair of the advisory committee for the Centre for Health Law, Policy and Ethics, at the University of Ottawa. Mr. Sweanor has been spearheading efforts to reduce cigarette smoking nationally and globally.
FDA medical oncologists discuss the July 7, 2017, approval of l-glutamine to reduce the acute complications of sickle cell disease.
Released August 17, 2017
Host: John J. Russell, MD
Guest: Harish Lavu, MD
Pancreatic cancer is projected to become the second leading cause of cancer-related death in the United States by 2020. This is due, in large part, to its insidious onset and subtle presentation even at late stages, many symptoms of which are often attributed to common and less serious conditions in aging populations.
Dr. Harish Lavu, Head of Hepatopancreatobiliary Surgery at Jefferson University, talks with host Dr. John Russell about the diagnostic and therapeutic priorities addressing pancreatic cancer, and why this disease is so hard to detect.
FDA medical oncologists discuss the approval of osimertinib for EGFR mutation-positive non-small cell lung cancer.
Released July 28, 2017
FDA medical oncologists discuss the FDA approvals of brigatinib and ceritinib for ALK-positive non-small cell lung cancer.
Released July 25, 2017
Host: Kathy King, RDN
Guest: Lise Alschuler, ND
Host Kathy King sits down with Dr. Lise Alschuler, naturopathic doctor, cancer survivor, and author of The Definitive Guide to Cancer: An Integrative Approach to Prevention, Treatment, and Healing. Dr. Alschuler is co-founder of iTHRIVEplan.com, a web application providing personalized wellness plans tailored to cancer survivors.
They talk about how integrative medicine specialists approach cancer: its causes, prevention strategies, and ways to include complementary therapies in patient treatments.
Host: Brian P. McDonough, MD, FAAFP
It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care?
Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.
The D.I.S.C.O. hosts discuss the agency’s first approval of pembrolizumab, a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Released May 30, 2017.
Host: Jennifer Caudle, DO
Guest: Major Kenneth Lee, IV, MD, PhD
Though a relatively rare disease, pancreatic cancer remains at the forefront of clinical discussion due to its highly aggressive nature. Dr. Major Kenneth Lee, Assistant Professor of Surgery at Penn Medicine, estimates that pancreatic cancer will become the number 2 cause of cancer death by the year 2020. This projected rise in mortality is largely due to the need for better advancement in treatment options.
Join host Dr. Jennifer Caudle and guest, Dr. Major Kenneth Lee, as they discuss major signs and symptoms associated with a pancreatic cancer diagnosis, risk factors, and treatment options.
FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.
Released May 22, 2017
FDA medical oncologists discuss the agency’s March 2017 approval of niraparib for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Released May 18, 2017
FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.
Released May 17, 2017
In the FDA's inaugural Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode, Dr. Richard Pazdur, director of the FDA Oncology Center of Excellence, talks with hosts Dr. Sanjeeve Bala and Dr. Abhilasha Nair about this new podcast series.
Host: Maurice Pickard, MD
Guest: Peter Dawson, MD
In the male-dominated world of medicine, she dared to step forward and fight for fairness—graduating from Johns Hopkins Medical School with honors in the year 1900. But for physician Dorothy Reed Mendenhall, MD, the battle for equality was just beginning.
In the name of improving the standards of care for women and infants, she faced the scorn of prejudiced doctors in an establishment marked by its unwillingness to change. Still, through the Gilded Age, two World Wars, and beyond, she kept up her fight—in the process, discovering new breakthroughs and saving lives, all while outperforming many of her male peers.
Dorothy in a Man’s World is an inside look at the life and career of Dr. Mendenhall, documented by physician and pathologist Dr. Peter Dawson. This biographical tribute to one of medicine’s great female pioneers showcases the struggles women faced to make a name for themselves in the world of health care—in addition to the drastic improvements which have been made in the specific area of care for women and their infants.
Dr. Dawson sits down with host Dr. Maurice Pickard as they explore Dr. Mendenhall's extraordinary life.
Host: Matt Birnholz, MD
Several new screening tests have been developed to help doctors find colorectal cancer early when it's most treatable and can reduce the burden of this disease and the death toll nationwide.
Host Dr. Matt Birnholz chats with Dr. John Kisiel, gastroenterologist and Assistant Professor of Medicine at Mayo Clinic College of Medicine, about new screening guidelines for detecting colorectal cancer.
Host: Caren Heller, MD
Guest: Francis Farraye, MD
Studies have shown that certain patients living with inflammatory bowel disease, or IBD, have a higher risk of developing colorectal cancer. In fact, IBD ranks as the third highest risk factor for the development of colorectal cancer.
Host Dr. Caren Heller, Chief Scientific Officer at the Crohn's & Colitis Foundation, sits down with Dr. Francis Farraye, gastroenterologist and Professor of Medicine and Co-Director of the Center for Digestive Disorders at Boston University School of Medicine. The two talk about making guidelines on endoscopic screening, surveillance, and detection of dysplasia more beneficial to IBD patients.
Host: Laura Wingate
Guest: Jason Ken Hou, MD, MS, FACG
Patients with inflammatory bowel diseases (IBD) are at a greater risk of developing anemia, a common complication that affects their quality of life and is associated with high rates of other IBD-related complications.
Host Laura Wingate, Vice President of Education, Support and Advocacy for the Crohn's & Colitis Foundation, chats with Dr. Jason Hou, Assistant Professor of Gastroenterology at Baylor College of Medicine about gaps in the importance of anemia management, diagnostics, and awareness for patients with IBD that continue to exist among healthcare providers.
Host: Matt Birnholz, MD
Guest: Taine Pechet, MD
Dr. Taine Pechet, chief of surgery at Penn Presbyterian Medical Center and associate professor of clinical surgery at Penn Medicine joins host Dr. Matt Birnholz to discuss his thoughts on who should be regularly screen for lung cancer and the various diagnostic techniques from his perspective as a thoracic surgeon. Dr. Pechet also discusses the surgical outcomes for these patient and his thoughts on what is on the horizon for the lung cancer field.
Host: Brian P. McDonough, MD, FAAFP
How can primary care clinicians best help women facing a diagnosis of breast cancer, and what counseling methods will guide them to optimal treatment plans?
Host Brian McDonough talks with Dr. Richard Bleicher, Director of the Breast Fellowship Training Program at Fox Chase Cancer Center, about strategies health care providers should take to help breast cancer patients deal with their diagnosis and prepare for the next steps in therapy.
Host: Matt Birnholz, MD
Guest: John Y.K. Lee, MD
Guest: Jason G. Newman, MD, FACS
Joining Dr. Matt Birnholz to discuss innovative surgical approaches to cranial base disorders are Doctors John Y. K. Lee and Jason G. Newman. Dr. Lee is Medical Director of the Gamma Knife Center and Associate Professor of Neurosurgery and Otorhinolaryngology-Head and Neck Surgery at the Pennsylvania Hospital. Dr. Newman is Associate Professor of Otorhinolaryngology-Head and Neck Surgery at the Center for Cranial Base Surgery at the University of Pennsylvania.
Host: Matt Birnholz, MD
Guest: Robin Zon, MD, FACP
Value-based, patient-centered care has become the destination for all branches of medicine, and is the philosophy driving modern payment reform initiatives like MACRA. But the unique care delivery needs in each specialty challenge the notion that one payment model can serve everyone. And nowhere has this become more relevant than in the field of oncology.
Dr. Matt Birnholz joins Dr. Robin Zon, practicing oncologist and vice president and senior partner at Michiana Hematology-Oncology in South Bend, Indiana. Dr. Zon serves as Chair-Elect of ASCO's Government Relations Committee was Past Chair of the Clinical Practice Committee, which alongside other stakeholders at ASCO developed a Patient-Centered Oncology Payment (PCOP) model. Recently, Dr. Zon presented this information at the recent AMA House of Delegates meeting in June. She speaks to the phases of this model, how it can function as a defined APM under MACRA, and its demonstrated positive impacts on oncology care pathways.
Host: Matt Birnholz, MD
The American Congress of Obstetricians and Gynecologists have made several recommendations regarding the practice of umbilical cord blood banking.
Host Dr. Matt Birnholz speaks with Dr. Jordan Perlow, Associate Director of Maternal-Fetal Medicine at Banner Good Samaritan Medical Center in Phoenix, AZ, about the newest guidelines set forth from ACOG.
[Read the Article]
The U.S. Preventative Services Task Force has updated the recommendations regarding colorectal cancer screening. The Task Force strongly recommends screening average risk adults age 50 to 75 for colorectal cancer, and then making individual screening decisions for adults age 76 to 85, taking into account the patient's overall health and screening history.
Colorectal cancer is the second leading cause of cancer death in the United States, and about one-third of adults in the United States have never been screened.
[Watch more videos of The JAMA Report]
Host: Kathy King, RDN
Guest: Diana Noland
How can our dietary choices affect and even influence cancer outcomes?
Host Kathy King talks with Diana Noland, dietitian and board-certified clinical nutritionist on the adjunct faculty of the University of Kansas Medical Center Department of Dietetics and Nutrition, and in private practice in Burbank, CA. Ms. Noland specializes in nutritional health for complex metabolic conditions, oncology, gastrointestinal, and neurologic chronic diseases. She speaks to the importance of proper nutrition for cancer patients; namely the roles that nutrition play in cancer treatment and specific nutritional problems cancer patients face.
Host: Michael Krychman, MD
Ovarian cancer is among the most highly prevalent and deadly cancers in existence, and in the struggle to care for patients and protect their quality of life, clinical standards in diagnostic screening and treatment protocols must change frequently.
Joining host Dr. Michael Krychman to discuss advances in treatment and prevention of ovarian cancer, with special focus on sexual health priorities, is guest Dr. Leslie Randall. Dr. Randall is Associate Professor of Obstetrics and Gynecology at the University of California-Irvine, and also Director of UC’s gynecologic oncology fellowship program.
[Read the Article]
In a new study, researchers from the University of California-Los Angeles studied tumor response and overall survival following the administration of a new treatment among patients with advanced melanoma. This agent, called pembrolizumab, is an antibody that blocks PD-1, a protein which prevents the body's immune system from attacking the cancer.
The researchers tested pembrolizumab on more than 650 patients in North America, Europe and Australia. They looked at tumor response before and after treatment and found that the lesions were smaller in about one third of patients. In patients who responded to the treatment, seventy-five percent maintained the response at one or two years.
[Watch more videos of The JAMA Report]
Host: Matt Birnholz, MD
Cannabis is gaining increased acceptance within the medical community for pain relief and other supportive care applications. But for oncology specialties, the use of cannabis may additionally extend into therapeutic purposes for patients.
From the floors of the A4M Conference in Las Vegas, Dr. Matt Birnholz speaks with Constance Finley, Founder and CEO of Constance Therapeutics, a California-based cannabis collective. The two discuss cannabis and cannabis oil applications for cancer patients, and their potential therapeutic effects.
Host: Barnett Mennen, MD
Guest: Angela DeMichele, MD, MSCE
Penn Medicine’s Breast Cancer Translational Center of Excellence (TCE), known as the 2-PREVENT TCE is led by Drs. Lewis Chodosh and Angela DeMichele. 2-PREVENT TCE aims to address one of the greatest challenges in breast cancer treatment: the high rate of relapse and late treatment effects among breast cancer survivors.
Host Dr. Barry Mennen welcomes Dr. Angela DeMichele, the Alan and Jill Miller Endowed Chair in Breast Cancer Excellence, Professor of Medicine and Epidemiology, and Co-Leader of the Breast Cancer Research Program at the Abramson Cancer Center of the University of Pennsylvania School Of Medicine.
Host: Jennifer Caudle, DO
Joining Dr. Jennifer Caudle to discuss top tips in breast cancer risk, screening, and detection is Dr. Monique Gary, breast surgical oncologist at Grand View Health in Sellersville, PA. Dr. Gary earned her medical degree from Philadelphia College of Osteopathic Medicine. She completed her internship and residency at University of Massachusetts Hospital and went on to complete her fellowship at Georgetown University Hospital.
Host: Shira Johnson, MD
Guest: Sunil Singhal, MD
The clinical ramifications for adding special fluorescent features to tumors at various stages of malignancy and penetration are enormous. But how do surgical, oncologic, and radiological specialists create these glowing tumors, what impacts do such markers have on clinical care, and which patient populations benefit most from this approach? Host Dr. Ashira Johnson welcomes Dr. Sunil Singhal, Director of the Thoracic Surgery Research Laboratory and Assistant Professor of Surgery at the University of Pennsylvania. Dr. Singhal reviews the use of fluorescence in tumors, articulating how new and emerging applications for this technology will advance the field of oncologic surgery.
Host: Barnett Mennen, MD
Guest: Maarouf Hoteit, MD
Hepatocellular carcinoma is one of the top ten causes of cancer death in the United States, and is the most rapidly increasing cause of cancer death in men. What's more, incidence rates are on the rise. For these reasons, understanding the nuances of early liver cancer detection, and treating underlying liver diseases prior to cancer development, have been more urgently needed.
Joining Dr. Barry Mennen to discuss diagnostic, medical, and surgical priorities for managing hepatocellular carcinoma is Dr. Maarouf Hoteit, Assistant Professor of Clinical Medicine, Director of the Multidisciplinary Liver Tumor Clinic, and Program Director of the Transplant Hepatology Fellowship at the University of Pennsylvania Perelman School of Medicine.
Host: Brian P. McDonough, MD, FAAFP
Guidelines in testing intervals and recommended methods for cervical cancer screening have been changing rapidly. What's the bottom line on helping primary care clinicians best protect their patients from this disease development? Joining Dr. Brian McDonough on the floors of Omnia Education's Women's Health Annual Visit in New York to discuss updated strategies drive down cervical cancer risk is Dr. Edward Mayeaux, Professor and Chairman of the Department of Family and Preventive Medicine at the University of South Carolina School of Medicine.
[Read the Article]
According to a new study, low dose aspirin taken regularly was associated with a reduced risk for cancer.
Researchers from Massachusetts General Hospital examined data from two large national studies that include about 136,000 men and women who have been providing detailed information about their overall health for decades.
Researchers identified 20,414 cancers among 88,084 women and 7,571 cancers among 47,881 men during a 32-year follow-up. Regular use of aspirin, two times or more per week, was associated with a 3 percent lower overall risk for cancer. This was mostly due to a 15 percent lower risk for gastrointestinal tract cancers and a 19 percent lower risk for cancers of the colon and rectum.
[Watch more videos of The JAMA Report]
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
From the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 75. Her lifetime chance of dying from ovarian cancer is about 1 in 100. Host Dr. Renee Allen is joined by Dr. Evelyn Reynolds to discuss critical updates in ovarian cancer, specifically dispelling the myth about ovarian cancer being a "silent killer." Dr. Reynolds an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine. She is board-certified in General Obstetrics and Gynecology and also Gynecologic Oncology.
[Read the Article]
Rates of genetic testing for BRCA1 and BRCA2 mutations have increased among younger women diagnosed with breast cancer, according to a new study. The study focused on nearly 900 women diagnosed with breast cancer at age 40 or younger. Researchers looked at rates of genetic testing, barriers to testing, and how the test results affected treatment decisions.
In 2006, the rates of BRCA testing were in the seventy percent range and by 2012 that proportion rose to ninety-five percent. While the majority of women reported being tested for BRCA 1 and 2, many were not, and a small minority reported that no one had discussed genetic risk or testing options. The study authors note that the overall goal of genetic testing is to help women make informed treatment decisions. Assessment of a young woman's genetic risk after a breast cancer diagnosis can affect treatment decisions and the results can also have health implications for her relatives.
[Watch more videos of The JAMA Report]
Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG
What is the role and importance of the Ob-Gyn Oncologist, especially for women diagnosed with pelvic cancers? What are some barriers patients face in seeing an Ob-Gyn Oncoloogist? And how can clinicians better partner with this group of specialists? In this episode, host Dr. Renee Allen explores answers to these questions with guest expert Dr. Evelyn Reynolds, board certified physician in both General Obstetrics & Gynecology and Gynecologic Oncology. She is also an Associate Professor and Division Director of Gynecologic Oncology at the Morehouse School of Medicine.
[Read the Article]
To some, end of life care in the United States is considered resource intensive, expensive, and inattentive to patients' needs. So how does the United States compare to other countries? A new study examined several health care measures at the end of life for cancer patients in five European countries, Canada and the United States.
Researchers from the University of Pennsylvania Perelman School of Medicine compared the health care experience for cancer patients older than 65, in Canada, Belgium, Germany, England, the Netherlands, Norway and the United States. They examined several clinical measures during the final six months of life.
The United States and Netherlands had the lowest percentage of patients dying in the hospital. The United States also had the fewest hospitalizations and the smallest number of days patients spent in the hospital. In contrast, intensive care admissions were twice as common in the United States compared to the other countries.
During the last six months of life, patients in Norway and Canada had higher hospital costs than patients in the United States. There was less spending in Germany and Belgium, but the lowest expenditures were in the Netherlands and …
Host: Brian P. McDonough, MD, FAAFP
On the subject of smoking, health risks differ from one form of smoking product to another. Yet these differences aren't always well understood by health professionals. Is there such a thing as a "safe" tobacco alternative, or is smoking cessation the only viable choice for risk reduction?Joining Dr. Brian McDonough to discuss the literature on tobacco harm reduction, as well as review the broadening spectrum of smoking formulations, from cigarettes to smokeless tobacco products to e-cigarette devices, is Dr. Brad Rodu, Endowed Chair in Tobacco Harm Reduction Research from the University of Louisville School of Medicine.
[Read the Article]
Glioblastoma is the most devastating form of brain cancer in adults; most patients die within one to two years of diagnosis. A new study examined whether using tumor-treating fields, a type of electromagnetic therapy, combined with maintenance chemotherapy in patients with glioblastoma who had already completed standard chemotherapy and radiation, could increase survival.
Researchers from University Hospital in Zurich, Switzerland are conducting a worldwide trial with 695 glioblastoma patients. One out of three received a standard maintenance course of chemotherapy, while the other two received maintenance therapy plus the tumor treating fields for up to two years.
The current results are for the first 315 patients. Researchers found that use of the tumor-treating fields increased both progression-free survival and overall survival. Overall survival is prolonged by an average of three months in patients getting the tumor-treating fields therapy.
[Watch more videos of The JAMA Report]
Host: Jennifer Caudle, DO
Guest: Gary M. Freedman, MD
Proton therapy is currently used to treat brain, spinal and prostate cancers, as well as many other tumors. Another potentially significant application is the treatment of breast cancer. Dr. Gary Freedman, Associate Professor of Radiation Oncology at the Hospital of the University of Pennsylvania, discusses advances in proton therapy in breast cancer in association with a national study currently underway at Penn Medicine.
Click here for more information about the active trials on proton for breast cancer, or you can visit clinicaltrials.gov for enrollment information.
[Read the Article]
In the United States, it is estimated that approximately 230,000 women will be diagnosed with breast cancer, and more than 40,000 will die from the disease this year alone. Early detection using mammography remains the best way to prevent premature death from breast cancer. A panel of experts examined decades of research to update the American Cancer Society's (ACS) recommendations for breast cancer screening. Based on this review, the 2015 recommendations for breast cancer screening for women at average risk of cancer include the following:
- Women should undergo regular screening mammography starting at age 45.
- Women 45 to 54 years of age should be screened annually.
- Women 55 years and older should transition to every other year screening or have the opportunity to continue annual screening.
- Women should have the opportunity to begin annual screening between the ages of 40 and 44 years.
- Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer.
- Clinical breast examination is not recommended for breast cancer screening among average-risk women of any age.
[Watch more videos of …
[Read the Article]
Successful treatment of stage II or stage III rectal cancer relies on surgical removal of the tumor. However, researchers from Baylor University Medical Center wanted to know if a "minimally invasive" procedure called a laparoscopy, would be as effective as a standard or "open" operation for patients with rectal cancer.
Researchers assigned 486 patients to receive either a standard open operation or the less invasive laparoscopic approach. All procedures were done by forty-six highly trained surgeons. Specimens from each procedure were examined to see whether all the tumor was removed ("complete resection").
Results found that 90 percent of the patients who underwent the open operation had a complete resection, where patients who underwent the laparoscopy only had an 81 percent success rate. The researchers concluded that these findings do not support laparoscopic removal of rectal cancer.
[Watch more videos of The JAMA Report]
JAMA Report videos provided pursuant to license. ©2015 American Medical Association, publisher of JAMA® and The JAMA Network® journals.
[Read the Article]
An increasing number of pregnant women are undergoing noninvasive prenatal testing to help identify fetal genetic abnormalities. This is done using a blood test that looks at the DNA of both the mother and fetus. In a small percentage of these tests, the results appear abnormal, but the baby's genetics are later shown to be normal. A new study examined if the rare diagnosis of maternal cancer could be one cause of such discrepancies. The study is being released to coincide with its presentation at the 19th International Conference on Prenatal Diagnosis and Therapy in Washington, D.C.
Researchers at Tufts Medical Center in Boston examined more than 125,000 noninvasive prenatal test results over the course of a two year period. Approximately 3,800 women had abnormal test results, and ten of those women were subsequently diagnosed with cancer. Medical records and additional genetic information were examined in eight of those women to look for patterns suggestive of underlying cancer.
Based on the results of the study, researchers estimate there is between a twenty and forty-four percent risk of maternal cancer if an abnormal number of chromosomes are detected. Further studies are needed to fully understand …
Host: Matt Birnholz, MD
Guest: Edward R. Sauter, MD, PhD, MHA
In the clinical arena, discussions on breast cancer prevention and treatment often center on what is considered most "cutting edge," from genetic mechanisms of disease to new combination pharmacotherapies to breast-conserving surgical innovations. But another field of study, targeting the potential roles of nutrition in breast cancer risk, remains commonly neglected by the medical community. What parts do nutritional choices and habits play in breast cancer development, and how can clinicians make better risk assessments given this information?
Dr. Edward Sauter, Professor of Surgery and Director of the Cancer Treatment and Prevention Center at the University of Texas Health Sciences Center, joins Dr. Matt Birnholz to discuss emerging connections between nutrition and breast cancer.
Dr. Carol Burke, Director of the Center for Colon Polyp and Cancer Prevention at the Cleveland Clinic, unveils ongoing but underrecognized gender disparities in the practice of gastroenterology, such as differences in academic vs private practice opportunities, average salaries and hours worked, rates of promotion and partnerships, and male-modeled endoscopic equipment designs. Dr. Burke then explores gender disparities in GI care for patients with colorectal cancer, including differences in efficacy of colorectal cancer screening, male vs female morbidity and mortality rates, and even the underlying biologies of cancers themselves.
Live from the floor of Digestive Disease Week in Washington DC, GI Insights presents two interviews focusing on screening, surveillance, and therapeutic updates for colorectal and liver cancers, hosted by Dr. Barry Mennen. Guests on this program include:
-
Dr. Linda Rabeneck, Vice President of Prevention and Cancer Control at Cancer Care Ontario (CCO), Professor of Medicine at the University of Toronto, and Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES) in Toronto. Dr. Rabeneck speaks on global initiatives to increase awareness about colorectal cancer screening and surveillance.
-
Dr. Kris Kowdley, Director of the Liver Care Network and Research Director of the Organ Care Program at Swedish Medical Center in Seattle, WA. Dr. Kowdley summarizes key takeaways on recognition of liver cancer and other related diseases of the liver in American populations today.
Host: Maurice Pickard, MD
Guest: Olufunmilayo (Funmi) Olopade, MD, FACP
Host Dr. Maurice Pickard welcomes Dr. Funmi Olopade, Walter L. Palmer Distinguished Service Professor in Medicine and Human Genetics, Director of the Hematology/Oncology Fellowship Program, and Director of the Center for Clinical Cancer Genetics at the University of Chicago. Dr. Olopade discusses disparities in health outcomes for black women with breast cancer. Dr. Olopade is an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer, having developed novel management strategies based on an understanding of the altered genes in individual patients. She stresses comprehensive risk reduction and prevention strategies in high-risk populations, as well as earlier detection through advanced imaging technologies.
Host: Lee Freedman, MD
Given the multitude of concerns a male patient with cancer must deal with, sexual dysfunction and infertility are two such concerns that often gets bypassed by clinicians addressing more "priority" issues. What kinds of challenges do these patients deal with, and how can physicians better assess and manage them? Joining Dr. Freedman to discuss sexual health and fertility in male cancer survivors is Dr. Puneet Masson, Director of the Male Infertility Program and Assistant Professor of Urology at Penn Medicine.
Host: Lee Freedman, MD
Osteosarcoma is a relatively rare but feared disease. What exactly is an osteosarcoma and how should it be worked up and treated? Host Dr. Lee Freedman discusses this diagnosis with Dr. Kristy Weber, Abramson Family Professor in Sarcoma Care Excellence and Professor, Vice-Chair of Faculty Affairs, Department of Orthopaedic Surgery; Director of the Sarcoma Program, Abramson Cancer Center; Chief, Orthopaedic Oncology.
Host: Lee Freedman, MD
Oropharyngeal cancer is part of a growing proportion of head and neck malignancies. This has also been associated with the increase in infection of the oropharynx by oncogenic strains of the human papillomavirus (HPV). And, transoral robotic surgery, or TORS, has allowed for minimally invasive surgery for HPV-related and non-HPV-related oropharyngeal cancer. To discuss this topic and much more, host Dr. Lee Freedman welcomes Dr. Gregory Weinstein, Professor and Vice Chair and the Director of the Division of Head and Neck Surgery. He is also the Co-Director of The Center for Head and Neck Cancer in The Department of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania.
Host: Ana Maria Rosario
Pancreatic Cancer strikes fear into the hearts of every practicing internist, pathologist, oncologist, and general surgeon on behalf of their patients, and unfortunately for us all, it’s on the rise. By 2030 it will be expected to climb to the number-2 spot for causes of cancer death. What new insights can we bring to the recognition and identification of pancreatic cancer to help curb that trend? Joining host Ana Maria Rosario at Omnia Education’s Stages in Women’s Health in New York is Dr. Aimee Lucas, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai in New York.
Host: Matt Birnholz, MD
Risk assessments for ovarian tumors are ever-evolving, as advances in diagnostic imaging and biomarker development pave the way. What are the current views on overian tumor risk assessment, and how should they be incorporated into clinical practice? Joining Dr. Matt Birnholz to address these questions is Dr. Fred Ueland, Professor of Obstetrics and Gynecology, and Director of Gynecologic Oncology at the University of Kentucky.
Host: Lee Freedman, MD
Presentation of lumps and bumps are common in the primary care setting, but the appropriate approach is vital to determine whether there may be a deeper problem. A better understanding can lead to more effective treatment. Expert guest Dr. Kristy Weber discusses musculoskeletal tumors during her discussion with host Dr. Lee Freedman. Dr. Weber is the Abramson Family Professor in Sarcoma Care Excellence as well as Professor, Vice-Chair of Faculty Affairs, Department of Orthopaedic Surgery; and Director of the Sarcoma Program, Abramson Cancer Center; and Chief, Orthopaedic Oncology.
Host: Maurice Pickard, MD
Recent data from the American Cancer Society documents over 14 million survivors of cancer living in the US at the present time. For these individuals, cancer rehabiliation is a critically important service that improves quality of life and, by extension, decreases morbidity and mortality rates. However, while cancer rehabilitation is mandated to be available to all cancer survivors throughout the US, not everyone has access to this care. How are healthcare systems addressing this disparity? Joining host Dr. Maurice Pickard to discuss this issue is Dr. Julie Silver, Associate Professor of Physical Medicine and Rehabilitation at Harvard Medical School and co-founder of Oncology Rehab Partners.
Host: Brian P. McDonough, MD, FAAFP
Dr. Randa Sifri is an Associate Professor of the Department of Family and Community Medicine in the Sydney Kimmel Medical College at Thomas Jefferson University, Director of Reasearch in the Department, and Research Fellowship Director. Listen as Dr. Brian McDonough interviews Dr. Sifri on early diagnosis, prevention, and recommended screenings for cancer in primary care patients.
Host: Ana Maria Rosario
Breast cancer screening is not the same as breast cancer risk assessment. What are the various screening procedures, what are their respective strengths and weaknesses, and how can clinicians best assess which tools to use for their patients? Senior correspondent Ana Maria Rosario welcomes Dr. William C. Dooley to provide an update on breast cancer screening. Dr. Dooley is the G. Rainey Williams Professor Chair in Surgical Breast Oncology at the University of Oklahoma Department of Surgery.
Host: Brian P. McDonough, MD, FAAFP
Dr. McDonough discusses how lowering patient sedentary time can prevent precancerous lesions according to a report in the American Association for Cancer Research.
Host: Matt Birnholz, MD
Dr. Andrew Wagner, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center, joins host Dr. Matt Birnholz to discuss the roles of the OB/GYN as both primary care providers and specialists in screening, diagnosing, and treating hereditary cancer syndromes in women. Their discussion covers cancers of the breast, ovaries, endometrium and cervix, as well as related heriditary conditions such as Lynch Syndrome.
Host: Lee Freedman, MD
What are the new advances in Head and Neck Cancer? What are the new trials in sparing patients' voice box? To answer these questions and more, host Dr. Lee Freedman is joined by radiation-oncologist Alexander Lin, MD, Assistant Chief, Head and Neck Service, University of Pennsylvania Department of Radiation Oncology and Director of Clinical Proton Operations, University of Pennsylvania, Department of Radiation Oncology at the Roberts Proton Therapy Center at the University of Pennsylvania.
Host: Lee Freedman, MD
The Philadelphia Chromosome provided the first evidence that genetic abnormalities were linked to cancer. This discovery at Penn Medicine more than 50 years ago ushered in the modern period of cytogenetics. Now, the Center for Personalized Diagnostics (CPD) builds on this legacy and is set to pave the way for a new era of genomic and therapeutic pathology. The Center is a joint initiative with the Abramson Cancer Center and integrates molecular genetics, pathology informatics and genomic pathology to empower physicians and patients to truly customize their treatment options accordingly. Host Dr. Lee Freedman welcomes Dr. David Roth, Chair of the Department of Pathology and Laboratory Medicine and Simon Flexner Professor of Pathology and Laboratory Medicine at Penn Medicine to discuss the unique Center and offerings for patients.
Host: Matt Birnholz, MD
Joining host Dr. Matt Birnholz is special guest, Dr. Clifford A. Hudis, President of the American Society of Clinical Oncology (ASCO) and Chief of the Breast Cancer Medicine Service and an attending physician at Memorial Sloan-Kettering Cancer Center. Dr. Hudis will provide an executive summary of the recently released State of Cancer Care in America: 2014 report, which will help cancer care providers, policy makers, and others more effectively shape the future of cancer care during these uncertain times.
Download and listen to this update!
And, to learn more about the websites that Dr. Hudis references in this interview, please visit:
- State of Cancer Care in America: 2014 report
- CancerLinq
This week, Mark and Margaret speak with Jack Andraka, 16 year old winner of last year's Intel Science and Engineering First Prize. Mr. Andraka has been nicamed the "Teen Prodigy of Pancreatic Cancer" by the Smithsonian for the device he created for early detection of pancreatic, ovarian and lung cancer. It's cheap, fast and accurate in numerous blind tests. He has been awarded by the White House, the Vatican, and the Royal College of Physicians, and he was deemed by his Lab Mentor at Johns Hopkins as the "Thomas Edison of our times."
Guest: Robert C. Young, MD
Host: Matt Birnholz, MD
The American Society of Clinical Oncology (ASCO) Conference brings over 30,000 people each year and has a membership of over 33,000, a third of which are international. Discussing important clinical research updates unveiled at this event by scientists from across the world is Dr. Robert C. Young, President of RCY Medicine in Philadelphia and past-President of ASCO. Dr. Young was also awarded ASCO's Distinguished Service Award for Scientific Leadership in 2004.
Host: Matt Birnholz, MD
This session of Grand Rounds explores the burden of human papillomavirus (HPV) -associated cancer and disease in the United States and prevention through HPV vaccination. Each year, there are an estimated 26,000 HPV-attributable cancers in the United States. About 17,000 occur in women, most of which are cervical cancers, and about 9,000 occur in men, most of which are oropharyngeal cancers. CDC estimates that $8 billion are spent each year on direct medical costs for preventing and treating HPV-associated disease.
This session provides more insight about the HPV vaccination program and how CDC, state and local health departments, and health care providers are working together to achieve high vaccination levels and reduce the substantial burden of HPV-associated disease.
This is Part 1 of a lecture in three parts.
Part 2 >>
Part 3 >>
To view the complete video recording of this and other CDC Public Health Grand Rounds sessions, visit http://www.cdc.gov/about/grand-rounds/
Host: Matt Birnholz, MD
National organizations such as the American Cancer Society and the American College of Obstetricians and Gynecology have published updated guidelines for cervical cancer screening. Crucial variations in these guidelines make implementing a sound, effective clinical protocol for management of gynecologic screening and treatment a challenge; and it is imperative that women's healthcare providers have a thorough understanding of clinical implications.
This Omnia Education program is presented by Dr. Thomas C. Wright, Jr., MD, Professor of Pathology at Columbia University College of Physicians and Surgeons.
Host: Matt Birnholz, MD
ReachMD, in cooperation with HealthDay, Presents Conference Coverage of the 47th annual meeting of the American Society of Clinical Oncology, held from June 3 to 7 in Chicago.
This year's meeting attracted more than 30,000 participants from around the world, including scientists, physicians, and allied health professionals. The conference featured the latest advances in clinical cancer research, with presentations focusing on patient and survivor care. Topics covered in presentations included cancer-related complications, quality-of-life management, and end-of-life care.
Host: Aaron Carroll, MD
Guest: Rodrigo M. Vianna, MD
Multivisceral transplant entails the transplant of nearly all the abdominal organs, with the exception of the kidneys. It is a highly unusual procedure, with only about 30-40 such surgeries occurring per year in the United States, compared to thousands of liver transplants performed annually, in only about seven transplant centers in the United States. Host Dr. Aaron Carroll welcomes Dr. Rodrigo Vianna, director of intestinal and multivisceral transplant at Indiana University Health, to discuss when multivisceral transplant can be used to treat patients with rare tumors, such as neuroendorcrine or desmoid tumors.